

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.



Cardiovascular Disease Risk Tests (for Louisiana Only)

Policy Number: CS015LA.~~NO~~
Effective Date: ~~October 1, 2023~~ TBD

[Instructions for Use](#)

Table of Contents	Page
Application	1
Coverage Rationale	1
Applicable Codes	2
Description of Services	3
Clinical Evidence	4
U.S. Food and Drug Administration	6
References	29
Policy History/Revision Information	34
Instructions for Use	35

Application

This Medical Policy only applies to the state of Louisiana.

Coverage Rationale

The following are unproven and not medically necessary due to insufficient evidence of efficacy:

- Arterial compliance testing, using waveform analysis as a method to determine risk for cardiovascular disease
- Carotid intima-media thickness (CIMT) measurement as an effective screening tool for the management of cardiovascular disease
- Advanced lipoprotein analysis [e.g., apolipoproteins, lipoprotein (a), subfractions or particle size] as method to determine risk for cardiovascular disease
- Lipoprotein-associated phospholipase A2 (Lp-PLA2) enzyme and other human A2 phospholipases such as secretory phospholipase A2 (sPLA2-IIA) as method to determine risk for cardiovascular disease or ischemic stroke
- Long-chain omega-3 fatty acids as method to determine risk for cardiovascular disease
- Endothelial function assessment using tools such as peripheral arterial tonometry (PAT) or brachial artery pressure ultrasound as a prognostic indicator to determine risk of cardiovascular disease
- ~~Multi-protein diagnostic biomarker, such as:~~
 - [Analysis of protein biomarkers by aptamer-based microarray and algorithm](#)
 - 3 proteins [high sensitivity (hs) troponin, adiponectin, and kidney injury molecule-1 (KIM-1)] ~~or~~ [with algorithm and reported as a risk score](#)
 - 4-proteins [NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 (TIMP-1), and KIM-1] with algorithm and reported as a risk score

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

- o 7 protein (IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3) with algorithm and reported as a risk score

Applicable Codes

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by federal, state, or contractual requirements and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

CPT Code	Description
<u>0019M</u>	<u>Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations</u>
*0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation
*0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD
*0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event
*0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)
<u>*0415U</u>	<u>Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS</u>
*82172	Apolipoprotein, each
83695	Lipoprotein (a)
83698	Lipoprotein-associated phospholipase A2 (Lp-PLA2)
83701	Lipoprotein, blood; high resolution fractionation and quantitation of lipoproteins including lipoprotein subclasses when performed (e.g., electrophoresis, ultracentrifugation)
83704	Lipoprotein, blood; quantitation of lipoprotein particle number(s) (e.g., by nuclear magnetic resonance spectroscopy), includes lipoprotein particle subclass(es), when performed
84999	Unlisted chemistry procedure

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

CPT Code	Description
93050	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive
93799	Unlisted cardiovascular service or procedure
93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral
*93998	Unlisted noninvasive vascular diagnostic study

CPT® is a registered trademark of the American Medical Association

Codes labeled with an asterisk (*) are not on the State of Louisiana Medicaid Fee Schedule and therefore are not covered by the State of Louisiana Medicaid Program.

Description of Services

Cardiovascular diseases (CVD), including coronary artery disease, stroke and hypertension, are the leading causes of morbidity and mortality in the United States. Vascular disease is the major contributor to cardiovascular morbid events and ideally is identified early, before symptoms are detected or irreversible damage has occurred. Arterial compliance (elasticity), carotid intima-media thickness (CIMT) and advanced lipoprotein analysis are tests that have been proposed to measure and monitor atherosclerosis.

Arterial endothelial dysfunction and endothelial damage, which play an important role in the atherosclerotic process, may result in reduced arterial compliance (elasticity) or increased arterial stiffness, especially in the smaller arteries. Arterial compliance can be measured by several techniques, many of which are invasive or clinically inappropriate. Direct methods include magnetic resonance imaging and ultrasound. Indirect methods include pulse wave velocity and augmentation index. At this time, there is no gold standard for arterial compliance measurement. Cardiovascular profiling using blood pressure waveform analysis (the rate at which pressure rises and falls during the cardiac cycle), provides a noninvasive assessment of arterial compliance. It is used for both large and small arteries by calculating pulse pressure, body surface area (BSA) and body mass index (BMI) to determine arterial compliance indices. These indices have been proposed as early indicators of CVD. Other noninvasive prognostic tools to assess endothelial functioning have been introduced as adjuncts to standard cardiovascular disease risk assessments (Roman et al., 2006). Specifically, these tools attempt to further stratify the risk of cardiovascular morbidity, while refining disease prevention measures. Two such assessment approaches involve the use of artery ultrasound testing and peripheral arterial tonometry using a fingertip pulse amplitude tonometry (PAT) device. Brachial artery ultrasound uses high-resolution ultrasound to assess changes in vascular dimensions, while the PAT records finger arterial pulse wave amplitude in response to reactive hyperemia. Increased finger pulse amplitude is posited to be a complex response to ischemia and reflects changes in digital flow and digital vessel dilation (Kuvini et al., 2007; Hamburg et al., 2008).

Measurement of carotid intima-media thickness (CIMT) for screening or management of cardiovascular diseases is based on the theory that the extent of carotid atherosclerosis correlates positively with the severity of coronary atherosclerosis. CIMT is a

noninvasive test using ultrasound to capture images of the carotid artery and computer software to analyze the measurements.

Cholesterol is a fat-like substance (lipid) that is present in cell membranes, and travels in the blood in distinct particles containing both lipid and proteins (lipoproteins). Three major classes of lipoproteins are found in the serum of a fasting individual: low density lipoproteins (LDL), high density lipoproteins (HDL), and very low-density lipoproteins (VLDL). LDL cholesterol typically makes up 60 - 70 percent of the total serum cholesterol and contains a single apolipoprotein, namely apo B-100 (apo B). HDL cholesterol normally makes up 20-30 percent of the total serum cholesterol. The major apolipoproteins of HDL are apo A-I and apo A-II. The VLDL are triglyceride-rich lipoproteins but contain 10-15 percent of the total serum cholesterol. Apolipoprotein, lipoprotein(a) and lipoprotein-associated phospholipase A2 are ~~emerging~~ risk factors being evaluated for their ability to predict cardiovascular disease or ischemic stroke (NHLBI, 2002).

Lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular inflammatory enzyme, has been investigated as a surrogate biomarker of increased coronary heart disease and stroke risk. Lp-PLA2 testing has been used as an adjunct to conventional risk assessment in healthy or asymptomatic adults to determine who might benefit from specific risk-reducing interventions, such as pharmacological therapies and behavior modification strategies. Secretory phospholipase A2-IIa (sPLA2) is a member of the PLA2 enzymes superfamily of pro-inflammatory enzymes. sPLA2 enzymes have been identified as potential risk markers for congestive heart disease (CHD) both from animal studies and observational analyses (Holmes et al. 2013).

The HART CADhs® is a multi-protein diagnostic test for determining whether a patient has heart disease and may be at imminent risk of a heart attack. HART CVE® is a multi-protein risk test for a patient's one-year risk of heart attack, stroke, or cardiac death. Artificial intelligence is employed to interrogate well-characterized clinical data sets to produce novel, multi-protein, algorithmically scored tests (Prevencio, 2022).

Clinical Evidence

Arterial Compliance

There is insufficient evidence to conclude that noninvasive arterial compliance testing is effective as a screening tool for the early detection of cardiovascular disease (CVD). There is inadequate clinical evidence from prospective studies that the use of this technology alters patient management and improves clinical outcomes. Additional research involving larger, well-designed studies is needed to establish the role of arterial compliance in the early identification, prevention and management of CVD.

Piko et al. (2021) performed a cross-section study, single-center evaluation of ankle-brachial index (ABI), mean carotid-femoral pulse wave velocity (cfPWV) and pulse wave analysis (PWA) parameters. All data was obtained in a 2-year period. One hundred and twenty-three patients who underwent elective coronary angiography were included. Ankle-brachial index (ABI) was measured, and arterial stiffness parameters were derived with applanation tonometry of the radial, carotid and femoral artery. Mean ABI was 1.04 ± 0.12 , mean subendocardial viability ratio (SEVR) $166.6 \pm 32.7\%$ and mean cfPWV 10.3 ± 2.4 m/s. Most of the patients ($n = 81$, 65.9%) had coronary artery disease (CAD). There was no difference in ABI among different degrees of CAD. Patients with zero- and three-vessel CAD had significantly lower values of SEVR, compared to patients with one- and two-vessel

CAD. No significant difference was observed in cfpWV values. Spearman's correlation test showed a correlation between ABI and SEVR and between ABI and cfpWV. Multiple regression analysis confirmed an association between cfpWV and ABI, cfpWV and mean arterial pressure, cfpWV and age and between cfpWV and body mass index, but not with arterial hypertension, dyslipidemia, diabetes mellitus or smoking status. SEVR was not statistically significantly associated with ABI using the same multiple regression model. The authors concluded that reduced ABI was associated with increased cfpWV, but not with advanced CAD or decreased SEVR. Limitations of the study included the cross-sectional design, small sample size and inclusion of only Caucasian patients.

In a systematic review and meta-analysis, Sequi-Dominguez et al. (2020) sought to estimate PWV and carotid femoral PWV performance predicting cardiovascular and all-cause mortality. In addition, the authors compared the results of cfpWV thresholds with already established values to increase its validity. Nine studies (n = 3,170) were included in the systematic review, and due to the limited studies measuring brachial-ankle pulse wave velocity (baPWV), only studies measuring cfpWV were incorporated in the main quantitative data synthesis. All included studies were of longitudinal nature two of them were cross-sectional analyses from longitudinal studies. The predictive performance of cfpWV pooled diagnostic odds ratio (dOR) values were 11.23 (95 % CI, 7.29-1.29) for cardiovascular mortality and 6.52 (95% CI, 4.03-10.55) for all-cause mortality. The area under the hierarchical summary receiver operating characteristic (HSROC) curve for cfpWV was 0.75 (95% CI, 0.69-0.81) for cardiovascular mortality and 0.78 (95% CI, 0.74-0.83) for all-cause mortality, where the closest cut-off point to the summary point was 10.7 and 11.5, respectively. The authors concluded that cfpWV is a useful cardiovascular and all-cause mortality predictor and it is a feasible, non-invasive and replicable method for estimating risk, and applicable in high-risk populations. Limitations of the study include publication bias, small sample size, specific population characteristics and cfpWV measurement technique differences. Additionally, the incremental value and clinical utility of this test were not reported.

Hitsumoto (2017) conducted a study to evaluate the impact of arterial velocity pulse index (AVI) as a novel marker of atherosclerosis using pulse wave analysis on high-sensitivity troponin T (hs-cTnT) in hypertensive patients. The study enrolled 455 patients without a history of cardiovascular events. AVI and hs-cTnT levels were measured. Hs-cTnT was detected in 405 patients (89.0%). AVI was significantly higher in patients with detectable hs-cTnT than in those without. In patients with detectable hs-cTnT, there was a significant positive correlation between AVI and hs-cTnT. The authors concluded that the significant relationship between AVI and hs-cTnT, as determined by multivariate analysis, indicated that arterial wave reflection is an important factor for the progression of subclinical myocardial damage in hypertensive patients. They identified some study limitations. First, treatment with antihypertensive drugs was stopped 24 hours or more before measurement to avoid influencing AVI. This time was not sufficient to mitigate the effects of long-acting drugs. Second, ultrasonic echocardiography, coronary angiography, and computed tomography angiography were not performed. Cardiovascular diseases such as heart failure or coronary artery disease may have gone undetected. Third, the sample size was relatively small. Prospective studies are required to clarify the clinical significance of AVI as a risk factor for cardiovascular disease in hypertensive patients.

Cheng et al. (2016) evaluated the prognostic value and clinical utilities of pulse wave analysis (PWA) derived mechanical biomarkers in two independent population-based cohorts. PWA on central arterial pressure waveforms were obtained from subjects without a prior history of cardiovascular diseases. The two studies were the Kinmen study (1,272

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

individuals, a median follow-up of 19.8 years); and the Cardiovascular Disease Risk Factors Two-Township Study (CVDFACTS) (2,221 individuals, median follow-up of 10 years). In the Kinmen study, right carotid artery pressure waveforms, which have been demonstrated to closely resemble central aortic pressure waveforms, were registered noninvasively with a tonometer. In the CVDFACTS study, central aortic pressure waveforms were obtained with a SphygmoCor device using radial arterial pressure waveforms. The associations between all mechanical biomarkers derived from pulse wave analysis and cardiovascular mortality were then examined in the multivariate Cox proportional hazards models that took into account cardiovascular risk factors including age, sex, systolic BP, body mass index, fasting glucose, triglycerides, low-density-lipoprotein cholesterol, and high-density-lipoprotein cholesterol, and smoking. Only systolic (SC) and diastolic rate constant (DC) of reservoir pressure could independently and consistently predict cardiovascular mortality in both cohorts. Cardiovascular mortality was higher in the Kinmen study due to higher hypertension prevalence and more male participants. During a median follow-up of 19.8 years, 315 (26.9%) deaths occurred (84 of cardiovascular origin). In the CVDFACTS study, a total of 171 deaths occurred (34 of cardiovascular origin) during a median follow-up of 10 years. Increased brachial systolic BP, pulse pressure, backward wave amplitudes (Pb), and augmentation index (AI) were significantly associated with increased cardiovascular mortality in both studies. Biomarkers derived from reservoir pressure-wave analysis were positively associated with cardiovascular mortality in the Kinmen study, and in the CVDFACTS study, only peak of reservoir pressure and DC remained significant in predicting cardiovascular mortality. The authors concluded that these findings suggested that mechanical biomarkers derived from pulse wave analysis could not only independently predict the long-term cardiovascular risks beyond the traditional risk factors, but also provide more accurate risk stratification by incorporating these mechanical biomarkers into the risk prediction models. It is not clear how this information will affect patient management.

Carotid Intima-Media Thickness (CIMT)

The clinical evidence is insufficient to show an added benefit of CIMT testing beyond traditional risk assessment. There is inadequate clinical evidence from prospective studies that the use of this technology alters patient management and improves clinical outcomes. Additional research involving larger, well-designed studies is needed to establish the role of arterial compliance in the early identification, prevention and management of CVD.

Tschiderer et al. (2023) conducted a meta-analysis on the relationship between CIMT and incident carotid plaque. The study included 21,494 participants without a history of cardiovascular disease and without preexisting carotid plaque at baseline from twenty prospective studies within the Proof-ATHERO (Prospective Studies of Atherosclerosis) consortium. The overall mean of baseline common carotid artery intima-media thickness (CCA-IMT) values was 0.71 mm, with 15 studies reporting mean CCA-IMT values and 5 studies reporting maximum CCA-IMT values. Over a median follow-up of 5.9 years 8278 individuals developed first-ever carotid plaque. The authors combined study-specific odds ratios (ORs) for incident carotid plaque using random-effects meta-analysis. In subgroup analyses, there was no significant effect modification across clinically relevant subgroups. Baseline CCA-IMT was approximately log-linearly associated with the odds of developing carotid plaque. The age-, sex-, and trial arm-adjusted OR for carotid plaque per SD higher baseline CCA-IMT was 1.40. The corresponding OR that was further adjusted for ethnicity, smoking, diabetes, body mass index, systolic blood pressure, low-and high-density lipoprotein cholesterol, and lipid-lowering and antihypertensive medication was 1.34. Sensitivity analysis restricted to studies defining plaque as focal thickening

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

yielded a comparable OR (1.38; 14 studies; 17 352 participants; 6991 incident plaques). The authors concluded the large-scale meta-analysis based on participant-level data, CCA-IMT is associated with the long-term risk of developing first-ever carotid plaque, independent of traditional cardiovascular risk factors. Limitations in the study were identified. Differences in how individual studies were defined and measured CCA-IMT and carotid plaque. The exact time point of plaque development. The long-term studies from 1990s to 2000s which use older ultrasound devices. The usage of 2-dimensional carotid plaque data versus 3-dimensional carotid plaque data. Furthermore, the study doesn't address the clinical utility of the test or how this technology alters patient management and improves clinical outcomes.

Nonterah et al. (2022) compared the association of established cardiovascular risk factors with carotid-intima media thickness (CIMT), a subclinical marker of atherosclerosis, between African, African American, Asian, European, and Hispanic populations. A cross-sectional analysis of 15 cohorts drawn from Africa, Asia, Europe, and North America, with a total of 34,025 individuals with a mean \pm SD age of 52 \pm 5 years and crude CIMT of 0.69 \pm 0.14 mm was conducted. The greatest CIMT adjusted for risk factors was the among African American populations followed by Asian, European, and Hispanic populations with African populations having the lowest mean CIMT. Men had higher CIMT levels in comparison with women. Age, sex, body mass index, and systolic blood pressure had a significant positive association with CIMT in all races and ethnicities at varying magnitudes. In comparison to European populations, the association of age, sex, and systolic blood pressure with CIMT was weaker in all races and ethnicities. In the Asian population, smoking, body mass index and glucose had the strongest positive association with CIMT when compared with all other racial and ethnic groups. In the African American and African populations only, high-density lipoprotein-cholesterol had significant protective effects. The authors concluded the magnitude of the associations of CVD risk factors with CIMT has implications for ethnic specific primary prevention strategies and offer insights into racial-and ethnic-specific mechanisms involved in the pathogenesis of CVD. Limitations in the study included the small sample size of the Asian and Hispanic population, the dietary intake data and not having medication use was not available across all the studies. Furthermore, the incremental value of CIMT and its clinical utility on patient care was not addressed.

Azcui Aparicio et al. (2021) conducted a systematic review to compare the predictive value of CIMT, carotid plaque identification, and CAC scoring for identifying sub-clinical atherosclerosis and assessing future risk of CVD in asymptomatic, low-to-intermediate risk individuals. A total of 30 studies (23 prospective cohort studies, 1 retrospective cohort study, 1 case-control study, and 5 cross-sectional studies) were included in the review with 92,498 participants. Follow-up duration in 11 studies was an average of 10.3 \pm 4.8 years and a median duration of 6.0 years. Inclusion of CAC scores yielded the highest HR ranging from 1.45 (95% CI, 1.11–1.88, p = 0.006) to 3.95 (95% CI, 2.97–5.27, p < 0.001), followed by maximum CIMT (HR 1.08; 95% CI, 1.06–1.11, p < 0.001 to 2.58; 95% CI, 1.83–3.62, p < 0.001) and carotid plaque presence (HR 1.21; 95% CI, 0.5–1.2, p = 0.39 to 2.43; 95% CI, 1.7–3.47, p < 0.001). The net reclassification index ranked higher with CAC (\geq 11.2%), followed by carotid plaque (\geq 2%) and CIMT (3%). The authors concluded that CAC scoring was superior compared to carotid plaque and CIMT measurements in asymptomatic individuals classified as being at low-to-intermediate risk. A limitation identified in this systematic review was the heterogeneity of ultrasound markers used in different papers, especially those for CIMT. Additionally, this study did not address how CIMT alters patient management and improves clinical outcomes.

Liu et al. (2020) conducted a meta-analysis to confirm whether carotid intima-media thickness (IMT) could serve as an accurate diagnostic method for coronary artery disease (CAD). A total of 22 articles were included in the study. The sensitivity and specificity of IMT for diagnosing CAD were 0.68 (0.57-0.77) and 0.70 (0.64-0.75), respectively. The area under the curve (AUC) was 0.74 (0.70-0.78). Subgroup analyses based on cutoff value of IMT demonstrated a cutoff value of 1 mm to be a more accurate diagnostic criteria for CAD (sensitivity: 0.66; specificity: 0.79; AUC: 0.80). The pooled results for sensitivity analysis were robust. Deek's funnel plot indicated no significant publication bias ($p = 0.195$). The authors concluded carotid IMT to be a suggestable screening tool for CAD. Limitations in the study were less Asian population studies in comparison to Caucasian population, and significant heterogeneity in the sensitivity and specificity analyses. Additionally, the analyses did not address the clinical utility of the test in improving patients'patients outcomes.

A meta-analysis of randomized clinical trials was performed by Willeit et al. (2020) to explore CIMT progression as a surrogate marker for different types of CVD end points defined as myocardial infarction, stroke, revascularization procedures, or fatal CVD. The study included 119 randomized controlled trials that involved 100,667 patients with a mean follow-up of 3.7 years. Of those patients, 12,038 developed the combined CVD end point. A 10 $\mu\text{m}/\text{y}$ slower CIMT progression was associated with a relative risk of 0.91 (95% CI, 0.87-0.94) for the principal outcome of CVD. The interventions reduced the CVD risk and resulted in relative risk of 0.92 (95% CI, 0.87-0.97) independent of their effects on CIMT progression. The authors estimated that interventions reducing CIMT progression by 10, 20, 30, or 40 $\mu\text{m}/\text{y}$ would yield relative risks of 0.84 (0.75-0.93), 0.76 (0.67-0.85), 0.69 (0.59-0.79), or 0.63 (0.52-0.74), respectively. The authors concluded that the effects of interventions on CIMT progression and on CVD risk are associated. Study limitations were identified. The type of therapeutic intervention was different across the included trials which may affect the CIMT surrogate value, and the individuals had different comorbidities. This study did not, however, address how integrating measurement of CIMT to clinical care alters patient management and improves clinical outcomes.

Kumar et al. (2020) conducted a meta-analysis to clarify the association between CCA-IMT with the risk of stroke. The study included 19 studies; sixteen studies involving 3,475 ischemic stroke (IS) cases and 11,826 controls; six studies with 902 large vessel disease (LVD) and 548 small vessel disease (SVD) of IS subtypes; five studies with 228 intracerebral hemorrhage (ICH) and 1,032 IS cases. The authors reported the results noted an association between increased CCA-IMT with risk of IS as compared to control subjects $+ (SMD = 1.46, 95\% CI = 0.90-2.02)$. There was an increased risk of LVD as compared to the SVD subtype of IS $+ (SMD = 0.36, 95\% CI = 0.19-0.52)$ and more chance of occurrence of IS rather than ICH $+ (SMD = 0.71, 95\% CI = 0.28-1.41)$. The authors concluded that carotid intima thickness measurements are associated with the risk of stroke and may be used as a diagnostic marker for predicting the risk of stroke events. Prospective studies embedded with larger sample size are needed to validate the findings.

The Jackson Heart Study (JHS) is the largest single-site, epidemiologic population-based study of African-Americans and was designed to better understand the etiology of cardiovascular, renal, and respiratory diseases in a community-based cohort. At the baseline examination (2000 to 2004) adults 21 to 94 years of age underwent bilateral far-wall CIMT measurement (mean 0.76 mm). Incident cardiovascular disease (CVD) events were then assessed over 7 to 11 years of follow-up. The study included 2,463 women and 1,338 men who were free of clinical CVD at baseline. Risk reclassification was only mildly improved by adding CIMT: Net Reclassification Index 0.13 and 0.05 for women and men, respectively; Integrated Discrimination Improvement 0.02 and 0.01 for women and men,

respectively. The authors concluded that CIMT was associated with incident CVD but provided modest incremental improvement in risk reclassification beyond traditional risk factors. They identified limitations of the study. First, the study was performed within a single geographical area, which may limit generalizability. Second, although the follow-up period was relatively long, 9.0 years is shorter than the 10-year period for which the Framingham risk score is calculated, and this may decrease the overall power of the observations. Third, carotid plaque was not systemically assessed. Finally, the impact of statins, antihypertensive, and antiplatelet medications during the ascertainment period is unknown (Villines et al., 2017).

Geisel et al. (2017) performed a study to compare the predictive value of coronary artery calcification (CAC), carotid intima-media thickness (CIMT) and ankle-brachial index (ABI) in a primary prevention cohort to determine which of the three markers improves cardiovascular (CV) risk discrimination best. The study included 3,108 participants without prevalent CV diseases from the population-based Heinz Nixdorf Recall study. Associations with incident major CV events (coronary event, stroke, CV death; (n = 223) were assessed during a follow-up period of 10.3 ± 2.8 years with Cox proportional regressions in the total cohort and stratified by Framingham risk score. All three markers were associated with CV events. The authors concluded that coronary artery calcification provides the best discrimination of risk compared with CIMT and ABI, particularly in the intermediate risk group, whereas CIMT may be an alternative measure for reassurance in the low-risk group.

A systematic review was conducted by Day et al. (2017) to investigate the association in children and young people between blood pressure and carotid intima-media thickness. A total of 28 studies were included. The results were mixed, with the largest and highest-quality studies suggesting an independent positive association between blood pressure and carotid intima-media thickness, even after adjustment for other cardiovascular risk factors. There was no indication of a clear threshold level for the effect of blood pressure on carotid intima-media thickness. There was insufficient data to support a pharmacological treatment threshold for the treatment of high blood pressure to prevent future cardiovascular disease. The studies included varied widely in terms of quality and design, and it was not possible to combine the data in a meta-analysis. The authors concluded that there is likely to be an independent association between blood pressure and carotid intima-media thickness in childhood, but it is not clear at what point this should be treated.

Den Ruijter et al. (2012) conducted a meta-analysis to determine whether the addition of CIMT measurements to the Framingham Risk Score added value in 10-year risk prediction of first-time myocardial infarctions or strokes. Individual data from studies were combined into one data set and a meta-analysis was performed on individuals without existing cardiovascular disease. Fourteen population-based cohorts of 45,828 individuals were included. During a median follow-up of 11 years, 4,007 first-time myocardial infarctions or strokes occurred. The authors concluded that adding CIMT measurements to the Framingham Risk Score was associated with a small improvement in 10-year risk prediction of first-time myocardial infarction or stroke, but this improvement is unlikely to be of clinical importance.

Advanced Lipoprotein Analysis

Studies report inconsistent results regarding the usefulness/incremental benefit of advanced lipoprotein testing over conventional risk factors or its clinical utility in changing management and improve clinical outcomes. Research has shown a lack of

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

universal, standardized testing modalities and patient selection criteria. Additional large, prospective studies are needed to establish whether measurement of these [emerging](#) markers will be more predictive of CVD than conventional lipid risk factors.

The Emerging Risk Factors Collaboration assessed whether adding various emerging lipid markers to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improved cardiovascular disease (CVD) risk prediction. Records were evaluated from 165,544 individuals without baseline CVD from 37 cohort studies in which apolipoprotein B (apoB) and apoA1, lipoprotein (a) [Lp (a)] or lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured. Participants received follow-up for 10 years, during which 15,126 CVD-related fatal and nonfatal outcomes occurred. Main outcome measures were CVD outcomes and low (< 10%), intermediate (10% to < 20%) and high risk (\geq 20%) prediction. The authors concluded that replacing information on total cholesterol and HDL-C with various lipid parameters did not significantly improve CVD risk prediction. (Di Angelantonio et al., 2012).

Lipoprotein (a) (Lp(a))

Orfanos et al. (2023) conducted a systematic review to report the burden of clinically relevant elevated lipoprotein (a) (Lp(a)) in secondary prevention atherosclerotic cardiovascular disease (ASCVD) population. Sixty-one studies met inclusion criteria. Of the included studies, 25 were observational studies and one clinical trial reported clinical burden of clinically relevant elevated Lp(a) levels. Major clinical outcomes included major adverse cardiovascular event (MACE; n=20), myocardial infarction (MI; n=11), revascularization (n=10), stroke (n=10), cardiovascular (CV) mortality (n=9), and all-cause mortality (n=10). The authors identified that the evidence showed significant association between elevated Lp(a) levels and an increased risk of MACE (n=15) as well as revascularization (n=8), while they demonstrated a trend for positive association with remaining CV outcomes. Meta-analysis was not feasible for included studies due to heterogeneity in Lp(a) thresholds, outcome definitions, and patient characteristics. Three studies reported humanistic burden. The authors findings deduced patients with elevated Lp(a) levels had higher odds of manifesting cognitive impairment and disability related to stroke. Elevated Lp(a) levels negatively correlated with health-related quality of life ($R=-0.166$, $p=0.014$) (n=1). A single study reported no association between elevated Lp(a) levels and economic burden. The authors concluded the systematic literature review demonstrated a significant association of elevated Lp(a) levels with major CV outcomes and increased humanistic burden in secondary prevention ASCVD population. The authors concluded that these results reinforce the need to quantify and manage Lp(a) for CV risk reduction and to perform further studies to characterize the economic burden. Limitations in the study were identified. None of the included studies reported the association between Lp(a) levels and CV outcomes in different ethnic subpopulations. The heterogeneity in patient population; reference thresholds (or low Lp(a) levels); comorbidities; biomarkers; gender distribution, risk factors for ASCVD; and definition of outcomes were additional limitations. Finally, limited studies evaluating the economic and humanistic burden of elevated Lp(a) was another key gap. The study did not address the clinical utility of measuring Lp(a) levels in changing management and improve clinical outcomes (Author Sang 2021 which was previously cited in this policy, is included in this systematic review).

Kumar et al. (2021) conducted a systematic review and meta-analysis to investigate the association of Lp(a) levels with the risks of stroke and its subtypes. The study included 41 observational studies involving 7,874 ischemic stroke (IS) patients and 32,138 controls; 13 studies for the IS subtypes based on Trial of Org 10,172 in Acute

Stroke Treatment (TOAST) classification and 7 studies with 871 Intracerebral hemorrhage (ICH) cases and 2,865 control subjects were included. The findings exhibited a significant association between increased levels of Lp(a) and risk of IS as compared to control subjects [standardized mean difference (SMD) 0.76; 95% confidence interval (CIs) 0.53-0.99]. Lp(a) levels were also found to be significantly associated with the risk of large artery atherosclerosis (LAA) subtype of IS (SMD 0.68; 95% CI 0.01-1.34) and the risk of ICH (SMD 0.65; 95% CI 0.13-1.17) as compared to controls. The authors concluded increased Lp(a) levels could be a predictive marker for identifying individuals who are at risk of developing IS, LAA and ICH. The meta-analysis revealed that increased levels of Lp(a) are significantly associated with the risk of IS in Asian as well as Caucasian population. Limitations in the study comprised of wide range variables of age, ethnicity, sample size, study-design; lack of original mean and standard deviation values of Lp(a) levels; non-availability of cut-of values of Lp(a); and the random-effects model used to account for the significant heterogeneity arising out of the studies. Furthermore, the study does not address the incremental value of Lp(a) to conventional risk factors or its clinical utility in improving outcomes.

~~Sang et al. (2021) conducted a study to investigate the association of lipoprotein(a) with long-term poor prognosis following acute coronary syndromes (ACS) in advanced-age patients. The study included 536 patients aged ≥ 80 years hospitalized for ACS. The primary outcomes were hard CHD events (a composite of fatal or non-fatal myocardial infarction, and CHD death). The secondary outcomes included major adverse cardiovascular events (MACEs), all-cause death and cardiac death. During a median 66-month follow-up, 89 hard CHD events occurred. Kaplan-Meier curves showed higher cumulative incidence of hard CHD events, MACEs, all-cause death and cardiac death in high lipoprotein(a) group than that in low lipoprotein(a) group. Multivariate Cox proportional hazards analyses revealed that elevated lipoprotein(a) levels were independently associated with an increased risk of hard CHD events [hazard ratio (HR): 1.714, 95% confidence interval (95%CI): 1.114-2.638], MACEs (HR 1.354, 95%CI: 1.024-1.790), all-cause death (HR 1.804, 95%CI: 1.286-2.532) and cardiac death (HR 1.891, 95%CI: 1.112-3.217). The authors concluded that elevated lipoprotein(a) levels were associated with an increased risk of hard CHD events, MACEs, all-cause death and cardiac death in the advanced-age patients with ACS, which indicated that routine screening for lipoprotein(a) might aid prognosis and risk assessment. This study did not address how integrating these measurements to clinical care alters patient management and improves clinical outcomes.~~

Shah et al. (2020) analyzed data from a randomized clinical trial to see the impact of elevated Lp(a) in a high-risk secondary prevention cohort of patients with diabetes on optimal medical treatment enrolled in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High Risk for Vascular Outcomes (ACCELERATE) trial to identify patients who could potentially benefit from Lp(a)-targeted treatment. Participants who met eligibility to enroll in the trial were divided into patients with and without diabetes to assess the impact of Lp(a) tertiles in each group. Baseline Lp(a) levels were measured. Participants were chosen from the placebo arm of the trial to limit any potential drug effect on the outcomes. The primary end point for this analysis was the first occurrence of any component of the composite cardiovascular death, myocardial infarction, stroke, coronary revascularization, or hospitalization for unstable angina. Patients were followed every 3 months after randomization with a median duration of 28 months. Overall, 5,121 patients (3,482 patients with diabetes, 1,639 without diabetes) in the placebo arm of ACCELERATE had baseline Lp(a) levels evaluated. A total of 3,426 had a diagnosis of type 2 diabetes, and 56 had a diagnosis of type 1 diabetes. A majority of patients were Caucasian males, and the average age of the entire

study population was 64 ±10 years. Baseline mean LDL cholesterol, mean HDL cholesterol, and median triglyceride levels were 81.6 ±27.9 mg/dL, 45.6 ±11.8 mg/dL, and 128.0 (93.0, 178.0) mg/dL, respectively. The median Lp(a) was 29.1 (10.8, 108.1) nmol/L. African Americans had a higher median Lp(a) compared with Caucasians and Asians (118.4 vs. 28.9 vs. 26.0 nmol/L, respectively). Participants without diabetes had higher median Lp(a) values compared with their counterparts with diabetes. Event rates for the composite end point were significantly higher in the highest tertile of Lp(a). The authors concluded that in a contemporary population of patients with high-risk established cardiovascular disease on optimal medical treatment, higher tertiles of Lp(a) were associated with increased cardiovascular events. This relationship of cardiovascular events was similar in patients with and without diabetes. They further recommended that based on their findings, at least a third of contemporary high-risk patients with diabetes on optimal medical treatment have high Lp(a) levels and increased risk for new cardiovascular events and might benefit from pharmacological intervention aimed at significantly reducing Lp(a) levels. This study did not address how integrating these measurements to clinical care alters patient management and improves clinical outcomes.

Kouvari and Panagiotakos (2019a) conducted a systematic review which outlined the current state of knowledge regarding the role of Lp(a) in primary and secondary CVD prevention. Searches resulted in the selection of $n=19$ studies. In the context of primary CVD prevention, $n=9$ cohorts, $n=2$ case-cohorts, and $n=2$ retrospective studies were identified, the majority of which suggested a significant positive association between Lp(a) and CVD onset. In terms of secondary CVD prevention, $n=5$ cohorts and $n=1$ case-cohort were considered as eligible highlighting from a positive to a neutral association between Lp(a) and CVD progression. The authors concluded that a positive association between Lp(a) and CVD seemed to be supported by a large body of evidence, yet it is comparatively moderate in magnitude and differentiates according to study population and the examined endpoints. This fact along with the lack of a definitive functional mechanism limits the potential connotation of Lp(a) in daily clinical practice.

The ATTICA prospective longitudinal cohort study was conducted during 2001-2012, and included 1,514 men and 1,528 women free of cardiovascular disease (CVD) from the greater Athens area, Greece (Kouvari et al., 2019b). Follow-up CVD assessment was achieved in 2,020 participants; baseline Lp(a) was measured in 1,890 participants. The recommended threshold of 50 mg/dL was used to define abnormal Lp(a) status. Ten-year CVD-event rate was 14% and 24% in participants with Lp(a) < 50 and Lp(a) ≥ 50 mg/dL, respectively. Multivariate analysis revealed that participants with Lp(a) ≥ 50 mg/dL versus Lp(a) < 50 mg/dL had about 2 times higher CVD risk [hazard ratio (HR) = 2.18, 95% confidence interval (CI) 1.11, 4.28]. The sex-based analysis revealed that the independent Lp(a) effect was retained only in men; in women, significance was lost after adjusting for lipid markers. Sensitivity analyses revealed that Lp(a) increased CVD risk only in case of abnormal high-density lipoprotein cholesterol, apolipoprotein A1, and triglycerides as well as low adherence to Mediterranean diet. The authors concluded that certain patient characteristics may be relevant when considering Lp(a) as a therapeutic or risk-prediction target.

Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, Waldeyer et al. (2017) analyzed data of 56,804 participants from 7 prospective population-based cohorts. The three endpoints considered were incident major coronary events (MCE), incident cardiovascular disease (CVD) events, and total mortality. Kaplan-Meier curves showed the highest event rate of MCE and CVD events for Lp(a) levels $\geq 90^{\text{th}}$

percentile. Cox regression models revealed a significant association of Lp(a) levels with MCE and CVD with a hazard ratio (HR) of 1.30 for MCE and of 1.25 for CVD for Lp(a) levels in the 67th–89th percentile and a HR of 1.49 for MCE and 1.44 for CVD for Lp(a) levels > 90th percentile vs. Lp(a) levels in the lowest third. There was no significant association between Lp(a) levels and total mortality. Subgroup analysis identified the highest Lp(a)-associated risk in individuals with diabetes HR for MCE 1.31 and for CVD 1.22 compared to those without diabetes, HR for MCE 1.15. No difference of the Lp(a)-associated risk were seen for other cardiovascular high-risk states. Two thousand four hundred and fifty-two incident MCE were observed during a median follow-up time of 8.8 years, 2,966 incident CVD events after a median of 8.7 years, and 48,774,877 deaths after a median of 9.2 years. The authors concluded that elevated Lp(a) was associated with an increased risk for MCE and CVD in individuals with diabetes and that these results may lead to better identification of target populations who might benefit from future Lp(a)-lowering therapies. Some limitations were identified. Differences in storage duration among the included cohorts may have contributed to differences in the Lp(a) levels across populations. Further, Lp(a) measurements were not performed consecutively so they could not correct for regression dilution bias.

~~Benderly et al. (2017) performed a study to evaluate the relevance of Lp-PLA to risk prediction among coronary heart disease (CHD) patients. Lp-PLA activity was measured in 2,538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study. Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA was associated with a hazard ratio (HR) of 1.12 [95% confidence interval (CI): 1.00–1.25] for mortality and 1.03 (0.93–1.14) for cardiovascular events. The authors concluded that Lp-PLA did not significantly improve model discrimination, or calibration and the results did not support added value of Lp-PLA for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.~~

Forbes et al. (2016) conducted a systematic review which assessed the relationship between ~~lipoprotein~~Lp(a) [Lp(a)] and cardiovascular disease (CVD) outcomes. The 60 studies included ten randomized control trials, 37 prospective cohort studies and 13 nested case control studies. Twenty out of 39 studies (52.3%) had a follow-up of 5 to ≤ 10 years and 11 out of 39 studies (28.2%) followed participants for over 10 yrs. The longest follow-up period was 20 years. The authors concluded that their review suggested that evidence is available to support an independent positive association between Lp(a) and the risk of future CVD events both in the general population and in high-risk populations, such as those with diabetes, hypertension, or on dialysis. Evidence also exists to support the positive independent association of Lp(a) mass with CVD events in secondary prevention populations. The number of studies for high-risk primary prevention populations and secondary prevention populations was limited. The analysis was limited by the inability to carry out statistical pooling/meta-analysis and the methods used to measure Lp(a) mass were poorly reported.

~~The Emerging Risk Factors Collaboration assessed whether adding various emerging lipid markers to total cholesterol and high density lipoprotein cholesterol (HDL-C) improved cardiovascular disease (CVD) risk prediction. Records were evaluated from 165,544 individuals without baseline CVD from 37 cohort studies in which apolipoprotein B (apoB) and apoA1, lipoprotein (a) [Lp(a)] or lipoprotein-associated phospholipase A2 (Lp-PLA2) were measured. Participants received follow-up for 10 years, during which 15,126 CVD-related fatal and nonfatal outcomes occurred. Main outcome measures were CVD outcomes and low (< 10%), intermediate (10% to < 20%) and high risk (> 20%) prediction. The authors concluded that replacing information on total cholesterol and HDL-C with various lipid~~

~~parameters did not significantly improve CVD risk prediction (Di Angelantonio et al., 2012).~~

Lipoprotein-Associated Phospholipase A2 (Lp-PLA2)

Given the low-quality ~~evidence and absence of important~~ evidence, no conclusions can be drawn regarding the clinical utility of Lp-PLA2 alone or in combination with other traditional biomarkers and/or risk assessments to determine the risk of CHD events in healthy or asymptomatic individuals. Additional well-designed clinical trials are necessary to establish the clinical utility of Lp-PLA2 and sPLA2-IIA for cardiovascular risk assessment and to determine the role of Lp-PLA2 as a potential adjunct to traditional risk assessment in the management of cardiovascular disease or stroke in adults.

Zhang et al. (2021) performed a prospective study to investigate the association between cardiovascular disease and Lp-PLA2. A total of 823 individuals at a high risk of stroke were screened and followed at 3, 6, 12, and 24 months. Among the 823 participants, 286 had varying degrees of carotid artery stenosis and 18 had cerebrovascular events. The level of Lp-PLA2 was higher in the group with cerebrovascular events than in the group without cerebrovascular events (662.81 \pm 111.25 vs. 559.86 \pm 130.05, $p < 0.001$). No statistical difference was found between the other parameters of the event group, such as HDL, LDL, and the no event group. The incidence of cerebrovascular events in the stenosis group was higher than that in the no stenosis group but no statistically significant difference was noted. The authors concluded that the level of Lp-PLA2 was positively correlated with the degree of carotid artery stenosis and predicted cerebrovascular events. There were some limitations of the study noted by the authors. The sample size was not large, the follow-up time was only 2 years, and the number of cerebrovascular events that eventually occurred was relatively small. The study was conducted at a single-center and the study population mainly included people aged > 40 years at a high risk of stroke, so the results of the study only represented a small part of the population. Furthermore, the study did not address how integrating measurements of Lp-PLA2 to clinical care alters patient management and improves clinical outcomes.

Hu et al. (2019) conducted a meta-analysis to determine whether elevated Lp-PLA2 is a risk factor for stroke. Twenty-two studies involving 157,693 participants were included for analysis. The RRs for overall stroke with 1 SD higher Lp-PLA2 activity and mass were 1.07 (95% CI 1.02-1.13) and 1.11 (95% CI 1.04-1.19), respectively. The RRs of ischemic stroke with 1 SD higher Lp-PLA2 activity and mass were 1.08 (95% CI 1.01-1.15) and 1.11 (95% CI 1.02-1.22), respectively. When comparing the highest and lowest levels of Lp-PLA2, the RRs of stroke for Lp-PLA2 activity and mass were 1.26 (95% CI 1.03-1.54) and 1.56 (95% CI 1.21-2.00), respectively. When comparing the highest and lowest levels of Lp-PLA2, the pooled RRs of ischemic stroke for Lp-PLA2 activity and mass were 1.29 (95% CI 1.07-1.56) and 1.68 (95% CI 1.12-2.53), respectively. The authors concluded that elevated Lp-PLA2 levels are associated with higher stroke risk. The authors identified some study limitations. The test methods for Lp-PLA2 were not uniform in the included studies, which is a potential source of bias and there was a lack of studies in individuals ≥ 65 years. Lp-PLA2 as a therapeutic target to prevent stroke requires further investigation. Furthermore, the study did not address how integrating measurements of Lp-PLA2 to clinical care alters patient management and improves clinical outcomes.

Benderly et al. (2017) performed a study to evaluate the relevance of Lp-PLA to risk prediction among coronary heart disease (CHD) patients. Lp-PLA activity was measured in

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

2,538 CHD patients included in the Bezafibrate Infarction Prevention (BIP) study. Adjusting for patient characteristics and traditional risk factors, 1 standard deviation of Lp-PLA was associated with a hazard ratio (HR) of 1.12 [95% confidence interval (CI): 1.00-1.25] for mortality and 1.03 (0.93-1.14) for cardiovascular events]. The authors concluded that Lp-PLA did not significantly improve model discrimination, or calibration and the results did not support added value of Lp-PLA for predicting cardiovascular events or mortality among CHD patients beyond traditional risk factor.

Younus et al. (2017) performed a systematic review to clarify the relationship between lipoprotein-associated phospholipase A2 (Lp-PLA2) and subclinical cardiovascular disease (CVD) as defined by coronary artery calcium (CAC), carotid intima-media thickness (CIMT) and endothelial function. Thirteen studies were included in the review, 6 examined the relationship between Lp-PLA2 and coronary artery calcification, of which 3 showed a significant correlation. Two studies examined the relationship between Lp-PLA2 and endothelial dysfunction, and 1 reported a significant relationship. Five studies investigated the association of Lp-PLA2 with carotid intima-media thickness, and 3 reported a significant relationship. The authors concluded that this review showed a variable association between Lp-PLA2, and subclinical disease and the results do not conclusively support the use of Lp-PLA2 in the diagnosis and management of subclinical CVD. Future research is needed to clarify what role Lp-PLA2 has in guiding treatment.

A systematic review with meta-analysis was conducted by Li et al. (2017a) to investigate the associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and the long-term risks of coronary heart disease (CHD) and ischemic stroke (IS) in the general population. Twelve prospective cohort studies were included. Combined hazard ratios for CHD and IS risks for the highest category referring to lowest category of Lp-PLA2 were 1.46 and 1.58 respectively. The same patterns were observed for both mass and activity, with the exception of those for CHD. For every 1-standard deviation (SD) increase in Lp-PLA2 activity, CHD risk increased by 12%; no association between 1-SD increases in Lp-PLA2 activity and IS was observed. Lp-PLA2 mass was associated with CHD risk. Lp-PLA2 mass per 1-SD increase was not associated with IS risk. The authors concluded that greater Lp-PLA2 activity or mass was associated with an increased risk of CHD and IS; however, additional well-designed trials are warranted to confirm this association.

A systematic review and meta-analysis was conducted by Tian et al. (2017) to assess the associations of Lp-PLA2 levels (mass and activity) with recurrent vascular events in patients with transient ischemic attack (TIA) and/or first ischemic stroke and with stroke in the general population. A total of 11 studies that comprised 20,284 participants (4,045 were TIA and/or first ischemic stroke patients and 16,239 were residents in general population) were identified. The pooled relative risk (RR) of recurrent vascular events (467 cases) in TIA and/or first ischemic group was 2.24, whereas the pooled RR of stroke (1,604 cases) in the general population was 1.47. The pooled RRs of Lp-PLA2 mass and activity levels with the risk of stroke in the general population were 1.69 and 1.28, respectively. The authors concluded that in patients with TIA and first ischemic stroke, elevated Lp-PLA2 activity levels were associated with recurrent vascular events and in the general population elevated Lp-PLA2 levels were associated with the risk of stroke.

Li et al. (2017b) conducted a meta-analysis to investigate the association between Lp-PLA2 and the prognosis of coronary heart disease (CHD). Fifteen studies with 30,857 participants were included. Overall, higher Lp-PLA2 activity or mass was not significantly related to increased risk of long-term all-cause mortality but was independently associated with an increased risk of long-term cardiovascular events. The

prognostic value of Lp-PLA2 in predicting cardiovascular events was observed in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2. The authors concluded that greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.

Liu et al. (2015) conducted a systematic review of the epidemiological studies on the relationship between Lp-PLA2 and atherosclerotic cardiovascular disease (CVD), to evaluate the relationship between Lp-PLA2 and the different stages of atherosclerosis. Thirty-three studies were included in the final analysis with 49,260 subjects. Among the 33 studies, 31 showed a positive association between increased Lp-PLA2 and high risk for incidence or mortality of total CVD, coronary heart disease (CHD) or stroke. The majority of the published studies suggest that Lp-PLA2 is closely associated with CVD events. High Lp-PLA2 was associated with increased risk for both first and recurrence of total CVD, CHD, and ischemic stroke. To understand the role of Lp-PLA2 in the early prevention and treatment of CVD, it is important to clarify the relationship between Lp-PLA2 and subclinical atherosclerosis. Studies on this relationship are limited. Most of previous studies were cross-sectional or case-control in nature and often showed conflicting results. The authors concluded that high Lp-PLA2 is associated with increased risk of clinical CVD events, while the association between Lp-PLA2 and subclinical atherosclerosis remains uncertain. Further prospective cohort studies on the relationship between Lp-PLA2 and subclinical atherosclerosis are warranted to determine whether Lp-PLA2 may only play a role in the progression of subclinical atherosclerosis to clinical events or both the initiation of the atherosclerosis and the progression.

Garg et al. (2015) evaluated associations of Lp-PLA2 and first-time cardiovascular events in a healthy multi-ethnic cohort characterized by presence or absence of baseline subclinical atherosclerosis. Lp-PLA2 mass and activity were measured at baseline in 5,456 participants in the Multi-Ethnic Study of Atherosclerosis. Individuals were characterized for presence of baseline subclinical disease (coronary artery calcium score > 0 or carotid intima-media thickness value > 80th percentile) and followed prospectively for development of cardiovascular disease (CVD) events. At 9-12-month intervals, participants or family members were contacted regarding interim hospital admissions, outpatient diagnoses of CVD, and deaths. Five hundred and sixteen CVD events occurred over a median follow-up of 10.2 years; 358 were due to coronary heart disease (CHD). Higher Lp-PLA2 mass and activity were both associated with increased incidence of CVD and CHD risk in individuals with or without baseline subclinical disease, defined by the presence of calcified coronary artery disease or a thickened carotid intima-media. Both Lp-PLA2 mass and activity were weakly correlated with carotid IMT and CAC. In the subset of patients on baseline statin therapy (n = 879), higher Lp-PLA2 mass was not associated with an increased risk of incident CVD or CHD. The authors concluded that Lp-PLA2 was positively associated with CVD and CHD risk, regardless of the presence of coronary artery calcium or a thickened carotid-intimal media. They did identify study limitations. The population included individuals with no known baseline clinical CVD and findings cannot be generalized to dissimilar populations. The number of CVD events was low for some strata in their stratified analyses. Other studies or longer-term follow-up is required to further investigate these questions. Lastly, their detection of atherosclerosis is based on surrogate measures and does not capture all participants with evidence of subclinical disease.

The Emerging Risk Factors Collaboration assessed whether adding various emerging lipid markers to total cholesterol and high-density lipoprotein cholesterol (HDL-C) improved cardiovascular disease (CVD) risk prediction. Records were evaluated from 165,544

individuals without baseline CVD from 37 cohort studies in which Lp-PLA2 was measured. Participants received follow-up for 10 years, during which 15,126 CVD-related fatal and nonfatal outcomes occurred. Main outcome measures were CVD outcomes and low (< 10%), intermediate (10% to < 20%) and high risk (\geq 20%) prediction. The authors concluded that replacing information on total cholesterol and HDL-C with various lipid parameters did not significantly improve CVD risk prediction (Di Angelantonio et al., 2012).

Secretory Phospholipase A2 (sPLA2)-IIA

It has been suggested that higher circulating levels of sPLA2 enzyme activity are associated with increased risk of cardiovascular events. However, it is not clear if this association is causal or how measurement of this marker improves clinical care or outcomes.

A nested case-control study was conducted by Smith et al. (2021) using data from the European Prospective Investigation into Cancer-Norfolk study. Cases (n = 145) in the current study were participants who developed ischemic stroke during follow-up, with controls (n = 290) matched in a 2:1 ratio based on age and sex. The aim of the study was to evaluate the association between both sPLA2 concentration and activity as continuous variables with risk of future ischemic stroke. The authors found that PLA2 activity levels were higher in cases than controls (4.6 nmol/min/ml, IQR 4.1-5.4 vs. 4.3 nmol/min/ml, IQR 3.7-4.9; p = 0.001). The differences in sPLA2 concentration were not found to be statistically significant. After adjusting for all confounding factors, sPLA2 concentration was again found not to be associated with risk of ischemic stroke: OR 1.02 (95% CI 0.99-1.04). However, sPLA2 activity was found to be associated with an increased risk: OR 1.23 (95% CI 1.01-1.49). The authors concluded that the activity of sPLA2, but not sPLA2 concentration, is associated with an increased risk of future ischemic stroke. The current study had some limitations. The participants were drawn from an EPIC-Norfolk CAD case-control study and the prevalence of cardiovascular risk factors in both cases and controls may be higher than in the general population. This was an observational study and further research with larger control trials is required. Furthermore, this study did not test how use of this marker improves clinical care or outcomes.

Guardiola et al. (2015) used genetic variants of PLA2G10, encoding sPLA2-X, to investigate the contribution of sPLA2-X to the measure of secretory phospholipase A2 (sPLA2) activity and coronary heart disease (CHD) risk traits and outcome. Three PLA2G10 tagging single-nucleotide polymorphisms (rs72546339, rs72546340, and rs4003232) and a previously studied PLA2G10 coding single-nucleotide polymorphism rs4003228, R38C, were genotyped in a nested case: control cohort drawn from the prospective EPIC-Norfolk Study (2,175 cases and 2,175 controls). Meta-analysis of rs4003228 (R38C) and CHD was performed using data from the Northwick Park Heart Study II and 2 published cohorts AtheroGene and SIPLAC, providing in total an additional 1,884 cases and 3,119 controls. EPIC-Norfolk subjects in the highest tertile of sPLA2 activity were older and had higher inflammatory markers compared with those in the lowest tertile for sPLA2 activity. None of the PLA2G10 tagging single-nucleotide polymorphism nor R38C, a functional variant, were significantly associated with sPLA2 activity, intermediate CHD risk traits, or CHD risk. The authors concluded that PLA2G10 variants are not significantly associated with plasma sPLA2 activity or with CHD risk.

Holmes et al. (2013) investigated the role of secretory phospholipase A2 (sPLA2)-IIA in cardiovascular disease. The authors conducted a Mendelian randomization meta-analysis of 19 general population and 10 studies in patients with acute coronary syndrome (ACS). They

identified a single nucleotide polymorphism (SNP) in PLA2G2A (rs11573156) that had a large and specific effect on circulating sPLA2-IIa mass and a small-to-modest effect on sPLA2 enzyme activity, but found no association between rs11573156 and incident, prevalent or recurrent major vascular event (MVE). The odds ratio (OR) for a major vascular event + (MVE+) was 1.02 in general populations and 0.96 in ACS cohorts. Instrumental variable analysis failed to show associations between sPLA2 enzyme activity and MVE. Higher sPLA2-IIa mass or sPLA2 enzyme activity may be a consequence not a cause of atherosclerosis. The authors concluded that reducing sPLA2-IIa mass is unlikely to be a useful therapeutic goal for preventing cardiovascular events.

Xin et al. (2013) investigated the potential association between serum sPLA2-IIa and prognosis in post-acute myocardial infarction (post-AMI) patients (n = 964). Elevated serum sPLA2-IIa during the convalescent stage of AMI predicted long-term mortality and readmission for heart failure (HF) after survival discharge in the post-AMI patients. Clinical data after discharge was obtained at 3 and 12 months after the onset of AMI, and annually thereafter up to 5 years. Patients with elevated serum sPLA2-IIa > 360 ng/dl (n = 164) were more likely to have diabetes mellitus, hypertension, HF, and multivessel disease compared to those with serum sPLA2-IIa ≤ 360 ng/dl. In addition, patients with elevated serum sPLA2-IIa had significantly lower HDL-cholesterol and higher LDL-cholesterol levels, compared to sPLA2-IIa ≤ 360 ng/dl subjects. During a median follow-up period of 1,462 days, 52 patients died, 31 had non-fatal reinfarction, and 40 were re-hospitalized for heart failure. Patients with elevated sPLA2-IIa had a significantly higher incidence of death (18.3% vs. 2.75%) and readmission for HF (14% vs. 2.1%) than those without, although no significant differences in the rate of nonfatal MI was detected between the 2 groups (4.88% vs. 2.87%). The authors concluded that elevated serum sPLA2-IIa served as an accurate predictor of long-term outcome and those patients with sPLA2-IIa > 360 ng/dl during the convalescent stage of AMI may be treated as at high risk for subsequent adverse events. This study did not address the benefits of using sPLA2 findings on health outcomes in patients with cardiovascular disease.

Multi-Protein Blood Test with Algorithm and Reported as a Risk Score

There is a lack of quality clinical evidence to conclude that multi-protein blood tests with algorithm and reported as a risk score are effective as a for the screening tool for the early detection or management of cardiovascular disease (CVD).

A Hayes (2023) Evidence Analysis Research Brief on HART CADhs blood test (Prevencio Inc.,) used to predict risk of obstructive coronary artery disease, sought to summarize the volume of publications to determine whether there is adequate published peer-reviewed literature to evaluate HART CADhs blood test (Prevencio Inc.). Hayes findings suggests that there currently is not enough published peer-reviewed literature to evaluate the evidence related to HART CADhs blood test (Prevencio Inc.) to predict risk of obstructive coronary artery disease (CAD) in a full assessment. One cross-sectional study was identified but no clinical utility studies evaluating HART CADhs for the prognosis of obstructive CAD were identified.

Mohebi et al. (2023) conducted a study using a panel of biomarkers developed via targeted proteomics to stratify the risk of developing CVE (CVE: incident myocardial infarction [MI], stroke, or cardiovascular death) following coronary angiography. The inclusion criteria included 446 patients with chronic kidney disease (CKD) over a 2-year follow up period. The 4 biomarkers (kidney injury molecule-1, Nterminal pro B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1) were integrated into a prognostic algorithm to predict CVE. 74 CVE were discovered; 51 events occurred in stage

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

1-2 CKD and 23 events occurred in stage 3-5 CKD. The C-statistic for predicting 2- years cardiovascular events in all 446 patients was 0.77. Considering patients at CVE lower-risk within each CKD staging group as a reference, the hazard ratio (95% confidence interval) of cardiovascular events was 2.82 for CKD stage 1-2/CVE higher-risk, and 8.32 for CKD stage 3-5/CVE higher-risk. The authors concluded biomarker panels prior to coronary catheterization may be useful to individualize CVE risk assessment among patients with CKD. The study however doesn't address the clinical utility of the test to improve clinical outcomes.

McCarthy et al. (2020) conducted an observational study of patients referred for coronary angiography, predictors of =70% coronary stenosis were identified from 6 clinical variables and 109 biomarkers. The study population included CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) derivation (n=636) and internal validation (n=275) cohorts. An externally validated cohort in the BACC (Biomarkers in Acute Cardiac Care) study included 241 patients presenting to the ED with suspected acute myocardial infarction where =50% coronary stenosis was considered significant. The resulting model consisted of 3 clinical variables (male sex, age, and previous percutaneous coronary intervention) and 3 biomarkers (hs-cTnI [high-sensitivity cardiac troponin I], adiponectin, and kidney injury molecule-1). In the internal validation cohort, the model yielded an area under the receiver operating characteristic curve (AUC) of 0.85 for coronary stenosis =70%. Dividing the risk score result into 5 levels resulted in a positive predictive value of 97% and a negative predictive value of 89% at the highest and lowest levels, respectively. In the external validation cohort, the score performed was similar with AUC of 0.86. In patients who had myocardial infarction neither ruled out nor ruled in via hs-cTnI testing ("indeterminate zone," n=65), the score had an AUC of 0.88. The authors concluded a model inclusive of hs-cTnI can predict the presence of obstructive CAD across a wide variety of patients with high accuracy including in those with indeterminate hs-cTnI concentrations. Limitations included single point in time measurements of biomarkers and obstructive CAD definitions differed in each cohort. The study doesn't address how the use of this model improves clinical outcomes or the management of CVD (This review is included in the Hayes 2023 Evidence Analysis Research Brief).

Neumann et al. (2020) performed a retrospective review to apply a novel risk-prediction model in a cohort of patients presenting with symptoms suggestive of MI to the emergency department. Four biomarkers [N-terminal pro B-type natriuretic peptide (NT-proBNP, ~~proBNP~~), kidney injury molecule-1 (KIM-1), osteopontin (OPN) and tissue inhibitor of metalloproteinase-1 (TIMP-1)] were tested on 750 patients. The end point was a composite of incident myocardial infarction or cardiovascular mortality. Twenty-two patients had a major adverse cardiovascular event (MACE) within 1 year. The median concentration of KIM-1 was 0.075 ng/ml compared with 0.024 ng/ml, in patients with and without a MACE, respectively; the median concentration of NT-proBNP 8,500 pg/ml compared with 870 pg/ml, in patients with and without a MACE, respectively; the median concentration of OPN was 62 ng/ml compared with 30 ng/ml, in patients with and without a MACE, respectively; and the median concentration of TIMP-1 was 152 ng/ml compared with 90 ng/ml, in patients with and without a MACE, respectively. The authors concluded that the study validated the high accuracy of a multiple biomarker panel to predict incident cardiovascular events in patients with suspected myocardial infarction. The absolute number of observed cardiovascular events was small and the overall sample size was limited to 750 individuals, which could impact the significance of findings. The study is limited by its retrospective observations. Furthermore, the design did not allow to assess whether the use of the score impacted care or patients' outcomes.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

There are two clinical trials underway to evaluate new cardiac biomarkers; The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases. ClinicalTrials.gov Identifier: NCT00842868 and Biomarkers in Acute Cardiac Care (BACC). ClinicalTrials.gov Identifier: NCT02355457.

Long-Chain Omega-3 Fatty Acids

There is insufficient evidence to conclude that measuring long-chain omega-3 fatty acids is effective ~~as a~~for screening ~~tool for the early detection or~~ management of cardiovascular disease (CVD). There is inadequate clinical evidence from prospective studies that the use of this technology alters patient management and improves clinical outcomes. Additional research involving larger, well-designed studies is needed to establish the role of arterial compliance in the early identification, prevention and management of CVD.

In a systematic review and meta-analysis, Zheng et al. (2022) sought to determine the role of LC n-3 PUFAs in the incidence of heart failure (HF). Thirteen studies met inclusion criteria and were included in the meta-analysis. Eight studies on dietary LC n-3 PUFA intake and incident HF included n=316,698 (11,244 incident HF cases), with a median follow-up of 10.7 years, for analysis. The studies showed that a higher dietary intake of LC n-3 PUFAs was associated with a lower risk of HF (highest versus lowest quintile: HR = 0.84, 95% CI = 0.75-0.94). Six studies, evaluating the association between circulating LC n-3 PUFA concentrations and the risk of HF comprising of n=17,163 (2520 HF cases) with a median follow-up of 9.7 years, showed that higher circulating LC n-3 PUFA concentrations were associated with a lower risk of HF. Higher circulating docosahexaenoic acid (DHA) concentrations were associated with a decreased risk of HF (top versus bottom quintile: HR = 0.44, 95% CI = 0.26-0.77). The associations between eicosapentaenoic acid (EPA) (HR = 0.58, 95% CI = 0.26-1.25), DHA (HR = 0.66, 95% CI = 0.24-1.82), and the risk of HF were not significant. The authors concluded higher LC n-3 PUFA concentrations measured by dietary intake or circulating biomarkers are associated with a lower risk of developing HF. Comparably, higher circulating LC n-3 PUFA concentrations appeared to play a protective role in the risk of HF. Future randomized controlled trials are required to evaluate whether LC n-3 PUFAs are effective in the primary prevention of HF. Limitations in the study included single measurement of LC n-3 PUFAs was performed in the observational studies and the association between individual LC n-3 PUFAs (DHA, EPA, and DPA) and the risk of HF are limited. Furthermore, comparison to other predictors of HF and the clinical utility of LC n-3 PUFA measurement are not address in this study.

Harris et al. (2021) conducted a meta-analysis to examine the associations between circulating levels of the n-3 PUFAs and mortality. The analysis was done with individual-level data from 17 prospective cohorts. Over a median of 16 years of follow-up, 15,720 deaths occurred among 42,466 individuals. Risk for death from all causes was significantly lower (by 15-18%) in the highest vs. the lowest quintile for circulating long chain (20-22 carbon) omega-3 fatty acids. Approximately 30% of the deaths were attributed to CVD, 30% to cancer, and the remaining 39% to all other causes. The authors concluded that in a global pooled analysis of prospective studies, LC n-3 PUFA levels were inversely associated with risk for death from all causes and from CVD, cancer, and other causes. Potential limitations: the hazard ratios (HRs) reported (instantaneous relative risk) may be modestly different than the cumulative relative risk and most individuals were White, potentially lowering generalizability to other races/ethnicities. Additionally, the study did not address whether measurement of LC n-3 PUFA levels improved patients care and outcomes.

In a multiethnic population-based cross-sectional study of 998 asymptomatic men aged 40-49 years (300 ~~US-U.S.~~-White, 101 ~~US-U.S.~~-Black, 287 Japanese American, and 310 Japanese in Japan), Mahajan et al. (2019) examined the relationship of serum LCn-3PUFAs to aortic calcification (measured by electron-beam computed tomography-). Overall, 56.5% participants had an aortic calcification score (AoCaS) > 0. The means (SD) of total LCn-3PUFAs, EPA, and DHA were 5.8% (3.3%), 1.4% (1.3%), and 3.7% (2.1%), respectively. In multivariable-adjusted Tobit regression, a 1-SD increase in total LCn-3PUFAs, EPA, and DHA was associated with 29% (95% CI Z 0.51, 1.00), 9% (95% CI Z 0.68, 1.23), and 35% (95% CI Z 0.46, 0.91) lower AoCaS, respectively. There was no significant interaction between race/ethnicity and total LCn-3PUFAs, EPA or DHA on aortic calcification. The authors concluded that this study showed the significant inverse association of LCn-3PUFAs with aortic calcification independent of conventional cardiovascular risk factors among men in the general population. This association appeared to be driven by DHA but not EPA. The study had limitations. First, the serum fatty acids composition has ~~a lot of~~ large day-to-day variations and reflect ~~recent~~ recent intake of fat and thus more likely to lead to misclassification bias than more stable markers of intake such as red blood cell fatty acids or adipose tissue fatty acids. Second, the study examined healthy men aged 40-49 years in Japan and the U.S.; therefore, the results of the study cannot be generalized to females, other populations, or age groups. Follow-up population-based studies are needed to further clarify the effect of LCn-3PUFAs on the incidence and progression of atherosclerosis.

Endothelial Function Assessment

There is insufficient evidence in the peer-reviewed medical literature to support the effectiveness and ~~prognostic~~ clinical utility of endothelial function assessment to establish the risk of cardiovascular disease. The majority of the identified studies reported some measure of statistical association of either peripheral arterial tonometry (PAT) or brachial artery ultrasound with cardiovascular disease. However, these associations are insufficient to demonstrate their clinical utility to effectively predict cardiovascular morbidity or change patient management and outcomes. Well-designed studies that extend beyond measures of simple statistical association are needed to demonstrate the clinical usefulness of such assessment tools to effectively predict cardiovascular events and classify patients according to their individual cardiovascular risk.

Cooper et al. (2021) performed a prospective observational study to assess associations between digital PAT measures and first-onset major cardiovascular disease events in a sample of FHS (Framingham Heart Study) participants. Using a fingertip PAT device, the pulse amplitude in Framingham Offspring and Third Generation participants (n = 3,865) were assessed at baseline and in 30-second intervals for 4 minutes during reactive hyperemia. The PAT ratio (relative hyperemia index) was calculated as the post-to-pre occlusion pulse signal ratio in the occluded arm, relative to the same ratio in the control (nonoccluded) arm. The Cox proportional hazards regression was used to relate PAT measures in the fingertip to incident CVD events. During follow-up (median, 9.2 years), 270 participants experienced new-onset CVD events. In multivariable models adjusted for cardiovascular risk factors, baseline pulse amplitude [hazard ratio (HR) per 1 SD, 1.04 (95% CI, 0.90-~~1.21~~); p = 0.57] and PAT ratio ~~+ [HR, 0.95 (95% CI, 0.84-1.08); p = 0.43]~~ were not significantly related to incident composite CVD events. Higher PAT ratio ~~+ [HR, 0.76 (95% CI, 0.61-0.94); p = 0.013]~~, but not baseline pulse amplitude [HR, 1.15 (95% CI, 0.89-~~1.49~~); 1];

$p = 0.29$, was related to lower risk for incident stroke. In a sensitivity analysis by stroke subtype, higher PAT ratio was related to lower risk of incident ischemic stroke events $[HR, 0.68 (95\% CI, 0.53-0.86); p = 0.001]$. The authors concluded that PAT measures were not associated with composite CVD events, lower PAT ratio—a measure of microvascular structure and function in the finger—was associated with greater risk of incident stroke. Further quality-controlled studies are needed to evaluate the association of PAT measures with cerebrovascular function and cognition.

Schnabel et al. (2021) evaluated the associations of noninvasive measures of flow-mediated dilatation and peripheral arterial tonometry with incident CVD and mortality in a cohort study. In a post-hoc analysis of the community-based Gutenberg Health Study, the brachial artery flow-mediated dilatation ($n = 12,599$) and fingertip peripheral arterial tonometry ($n = 11,125$) were measured. After a follow-up of up to 11.7 years, there were 595 incident CVD events, 106 cardiac deaths, and 860 deaths in total. Noninvasive measures of peripheral vascular structure and function did not reveal clinically relevant associations with incident cardiovascular disease or mortality. The authors concluded that routine measurement of flow-mediated dilation or peripheral arterial tonometry in the community cohort to screen for high risk of cardiovascular disease or mortality was not effective and whether determination of pulse amplitude by peripheral arterial tonometry improves clinical decision-making in primary prevention needs to be demonstrated.

A study by Venuraju et al. (2019) aimed to determine prognostic factors for endothelial dysfunction and identify relationships between reactive hyperemia index (RHI) score, clinically relevant coronary artery disease ($> 50\%$ stenosis), and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes mellitus (T2DM). Endothelial function was assessed using peripheral arterial tonometry and correlated with patient characteristics and cardiovascular outcomes during a median follow-up of 22.8 months. Among 235 patients with a median duration of T2DM of 13 years, mean (standard deviation) RHI score was 2.00. Serum low- and high-density lipoprotein cholesterol levels positively and negatively predicted RHI score, respectively. Median coronary artery calcium (CAC) score was 109 Agatston units, but no correlation between CAC and RHI scores was observed. The RHI score did not predict the number or severity of coronary plaques identified using computed tomography coronary angiography. Additionally, there was no association between RHI score and the risk of a MACE during follow-up. Overall, endothelial function was not predictive of CAC score, extent, and severity of coronary plaque or MACEs and did not demonstrate utility in cardiovascular risk stratifying patients with T2DM.

Van den Heuvel et al. (2015) examined the applicability of PAT to detect a low risk of coronary artery disease (CAD) in a chest pain clinic. In 93 patients, PAT was performed resulting in RHI and augmentation (AIx) indices. Patients were risk classified according to HeartScore, Diamond and Forrester pretest probability (DF), exercise testing (X-ECG), and computed tomography calcium scoring (CCS) and angiography (CTA). Correlations, risk group differences and prediction of revascularization within 1 year were calculated. RHI correlated with HeartScore, AIx with DF but both were not significantly different between normal and ischemic X-ECG groups. RHI and AIx were similar between low risk as compared with intermediate-to-high risk and failed to predict revascularization. The authors concluded that PAT cannot detect a low risk of CAD, possibly because RHI and AIx versus X-ECG, CCS and CTA represent independent processes.

Rubenstein et al. (2010) examined whether endothelial dysfunction, as detected by non-invasive peripheral arterial tonometry (EndoPAT), can predict late cardiovascular events

(n = 270). Once reactive hyperemia (RH) was manually induced, patients were evaluated over a 7-year follow-up period for subsequent cardiovascular adverse events, such as cardiac death, myocardial infarction, revascularization or cardiac hospitalization. Cox regression models were used to estimate the association of EndoPAT results with adverse events, adjusted for age. Univariate predictors of adverse events were natural logarithmic scaled RH index (LRHI), advancing age, and prior coronary bypass surgery. Multivariate analysis identified LRHI value of less than 0.4 as an independent predictor of cardiovascular events.

In a correlation study of Framingham Heart Study participants (n = 1,957), Hamburg et al. (2008) evaluated the relationship between digital pulse amplitude using a fingertip (PAT) device and cardiovascular disease risk factors. Initial findings demonstrated that manually induced, reactive hyperemia resulted in a time-dependent increase in fingertip pulse amplitude. Based on a stepwise, multivariate, linear regression model, a number of risk factors were inversely related to the hyperemic response (PAT ratio), including being male, body mass index (BMI), total/high density lipoprotein (HDL) cholesterol, diabetes, smoking, and lipid-lowering treatment. Conversely, increasing age was positively correlated with PAT ratio (p < 0.01). These results may suggest a link between certain risk factors and lower digital hyperemic response. However, a causal relationship between these risk factors and digital vascular function could not be established. Given the homogenous nature of the study participants (Caucasian individuals of European descent), the preliminary results are also not generalizable to different ethnic or racial groups. Despite these positive preliminary findings, the clinical utility and predictive value of digital pulse amplitude have yet to be established.

Clinical Practice Guidelines

American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE)

A 2020 Consensus Statement by the AACE and ACE on the management of dyslipidemia and prevention of cardiovascular disease algorithm makes the following recommendation:

Measurement of Lp_a in individuals should be considered in the following settings:

- All individuals with clinical ASCVD, especially premature or recurrent ASCVD despite LDL-C lowering
- Individuals with a family history of premature ASCVD and/or increased Lp_a
- Individuals with South Asian or African ancestry, especially with a family history of ASCVD or increased Lp_a
- Individuals with a 10-year ASCVD risk $\geq 10\%$ (primary prevention setting), in order to stratify risk
- Patients with a personal or family history of aortic valve stenosis
- Patients with refractory elevations of LDL-C despite aggressive LDL-C-lowering therapy (i.e., statin resistance)

(Handelsman et al., 2020)

The 2017 AACE guidelines for management of dyslipidemia and prevention of cardiovascular disease make the following recommendations:

- Carotid Intima Media Thickness: CIMT may be considered to refine risk stratification to determine the need for more aggressive atherosclerotic cardiovascular disease (ASCVD) preventive strategies (Intermediate level of evidence and recommendation grade)

- Apolipoprotein B: For individuals at increased risk of ASCVD, including those with diabetes, an optimal apolipoprotein B (apo B) goal is < 90 mg/dL, while for individuals with established ASCVD or diabetes plus 1 or more additional risk factor(s), an optimal apo B goal is < 80 mg/dL, and for individuals at extreme risk, an optimal apo B goal is < 70 mg/dL (Strong level of evidence and recommendation grade)
- Lipoprotein (a): Testing for lipoprotein (a) is not generally recommended, although it may provide useful information to assign risk in Caucasians with ASCVD, those with an unexplained family history of early ASCVD, or those with unknown family history such as adopted individuals
- Lipoprotein-Associated Phospholipase A2: Measuring lipoprotein-associated phospholipase A2 (Lp-PLA2) in some studies has demonstrated more specificity than hsCRP, when it is necessary to further stratify an individual's ASCVD risk, especially in the presence of hsCRP elevations (Strong level of evidence and recommendation grade)

American College of Cardiology (ACC)/American Heart Association (AHA)

A 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease identifies the following risk enhancing factors for clinician-patient risk discussion:

- Lipids/biomarkers associated with increased ASCVD risk:
 - Persistently elevated primary hypertriglyceridemia (≥ 175 mg/dL, nonfasting non-fasting)
 - If measured:
 - Elevated high-sensitivity C-reactive protein (≥ 2.0 mg/L)
 - Elevated lipoprotein (a): A relative indication for its measurement is family history of premature ASCVD. A lipoprotein (a) ≥ 50 mg/dL or ≥ 125 nmol/L constitutes a risk-enhancing factor, especially at higher levels of lipoprotein (a)
 - Elevated apolipoprotein B (≥ 130 mg/dL): A relative indication for its measurement would be triglyceride ≥ 200 mg/dL. A level ≥ 130 mg/dL corresponds to an LDL-C > 160 mg/dL and constitutes a risk-enhancing factor
 - Ankle-brachial index (< 0.9)

A 2013 ACC/AHA guideline makes the following recommendations on the assessment of initial CVD event risk:

- Carotid Intima-Media Thickness: CIMT is not recommended for routine measurement in clinical practice for initial CVD event risk assessment
- Advanced Lipoprotein Analysis: The contribution to initial CVD event risk assessment using apolipoprotein B is uncertain

A 2010 ACC/AHA Task Force makes the following recommendations on assessing cardiovascular risk in asymptomatic adults:

- Arterial Compliance: ACC/AHA guidelines for the assessment of cardiovascular risk in asymptomatic adults state that measures of arterial stiffness outside of research settings are not recommended. Class III, Level of Evidence C recommendation - no benefit; very limited populations evaluated
- Carotid Intima Media Thickness: ACC/AHA guidelines for the assessment of cardiovascular risk in asymptomatic adults state that measurement of carotid artery IMT is reasonable for asymptomatic adults at intermediate risk. Published recommendations on required equipment, technical approach and operator training and experience for performance of the test must be carefully followed to achieve high-

quality results. Class IIa, Level of Evidence B recommendation - conflicting evidence but the panel recommends in favor of testing

- **Advanced Lipoprotein Analysis:** ACC/AHA guidelines for the assessment of cardiovascular risk in asymptomatic adults state that measurement of lipid parameters, including lipoproteins and apolipoproteins beyond a standard fasting lipid profile is not recommended. Class III, Level of Evidence C recommendation - no benefit; very limited populations evaluated
- **Lipoprotein-Associated Phospholipase A2:** ACC/AHA guidelines for the assessment of cardiovascular risk in asymptomatic adults state that lipoprotein-associated phospholipase A2 (Lp-PLA2) might be reasonable for cardiovascular risk assessment in intermediate-risk asymptomatic adults. The report also states that, at this time, there is no information indicating that Lp-PLA2 levels are clinically effective for motivating patients, guiding treatment or improving outcomes. Class IIb, Level of Evidence B - conflicting evidence and usefulness/efficacy of test is less well established
- **Long-Chain Omega-3 Fatty Acids:** ACC/AHA guidelines for the assessment of cardiovascular risk in asymptomatic adults do not address this test as a measure of cardiovascular risk
- **Brachial/Peripheral Flow-Mediated Dilation:** ACC/AHA guidelines for the assessment of cardiovascular risk in asymptomatic adults state that peripheral arterial flow-mediated dilation (FMD) studies are not recommended for cardiovascular risk assessment in asymptomatic adults. Class III, Level of Evidence B - no benefit. The guideline also states that it is unclear whether measures of peripheral endothelial health provide incremental predictive information when controlling for traditional risk factors

American Diabetes Association (ADA)

ADA 2022 guideline on cardiovascular disease and risk management states that risk scores and other cardiovascular biomarkers have been developed for risk stratification of secondary prevention patients (i.e., those who are already high risk because they have ASCVD) but are not yet in widespread use. With newer, more expensive lipid-lowering therapies now available, use of these risk assessments may help target these new therapies to "higher risk" ASCVD patients in the future.

American Heart Association (AHA)

A 2022 scientific statement from the American Heart Association on clinical use of lipoprotein(a) stated the following:

- Elevated Lp(a) is causal for ASCVD and could inform clinical decision-making regarding risk management
- Lp(a) levels are largely determined by genetic factors
- Further studies are necessary to understand the mechanistic links between apo(a) isoforms and risk for ASCVD; pathways for Lp(a) synthesis, regulation, and metabolism; and Lp(a)-associated risk in diverse genetic and environmental contexts (Reyes-Soffer et al., 2022)

American Heart Association (AHA)/American College of Cardiology (ACC)/American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR)/American Academy of Physician Assistants (AAPA)/Association of Black Cardiologists (ABC)/American College of Preventive Medicine (ACPM)/American Diabetes Association (ADA)/American Geriatrics

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Society (AGS)/American Pharmacists Association (APhA)/American Society for Preventive Cardiology (ASPC)/National Lipid Association (NLA)/Preventive Cardiovascular Nurses Association (PCNA)

A 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol makes the following statements on the measurements of apolipoprotein B and lipoprotein (a):

- A relative indication for apolipoprotein B measurement would be triglyceride ≥ 200 mg/dL. A persistent elevation of apoB can be considered a risk-enhancing factor
- Indications for Lp(a) measurement are family history of premature atherosclerotic cardiovascular disease (ASCVD) or personal history of ASCVD not explained by major risk factors. An elevation of Lp(a) is considered to be a risk-enhancing factor. This is especially in those with higher Lp(a) values and, if used in women, only in the presence of hypercholesterolemia

American Heart Association (AHA)/American Stroke Association Stroke Council (ASA)

The 2014 AHA/ASA guideline on primary prevention of stroke states the following:

- Measurement of inflammatory markers such as Lp-PLA2 in patients without cardiovascular disease may be considered to identify patients who may be at increased risk of stroke, although their usefulness in routine clinical practice is not well established
- The clinical benefit of using Lp(a) in stroke risk prediction is not well established

American Society for Clinical Pathology (ASCP)

The ASCP recommends against routinely ordering expanded lipid panels (particle sizing, nuclear magnetic resonance) as screening tests for cardiovascular disease (ASCP, 2020).

Canadian Society of Clinical Chemists (CSCC)/Canadian Cardiovascular Society (CCS)

The 2021 CSCC clinical laboratory lipid reporting recommendations based on the 2021 CCS guidelines on the management of dyslipidemia for the prevention of cardiovascular disease in the adult states the following:

- Recommend laboratories offer non fasting and fasting lipid assessment.
- Recommend laboratories offer a lipid panel consisting of total cholesterol, LDL-C, HDL-C, non-HDL-C, and triglycerides. ApoB and Lp(a) should be offered only as individually orderable tests.
- Recommend laboratories adopt a lipid reporting format that includes lipid decision thresholds on the basis of lipid screening in primary prevention patients.
- Include minimal interpretive comments on the lipid report with reference to the 2021 CCS guidelines, where applicable.
- Recommend that all laboratories should offer Lp(a), either as an in-house or send-out test, using assays that quantify apolipoprotein (a) [Apo(a)] in molar units (nmol/L), and that the assay is stated in the report.
- Recommend implementation of the new NIH equation, rather than the Friedewald equation, for calculating LDL-C in all patients (White-Al Habeeb, 2022).

Endocrine Society (ES)

In a clinical guideline on lipid management in patients with endocrine disorders, the Endocrine Society states that advanced lipid testing may be helpful in further characterizing lipid abnormalities, but studies have not provided conclusive evidence that measurement of particle size or density adds to CVD prediction beyond the standard lipid risk factors (Newman, 2020).

European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS)

The ESC/EAS 2019 Dyslipidemia Clinical Practice Guideline recommendations include the following:

- Measurement of lipoprotein(a) [Lp(a)] at least once in each adult's lifetime to identify those with very high inherited Lp(a) levels above 180 mg/dL (> 430 nmol/L) who may have a lifetime risk of atherosclerotic CV disease (ASCVD) that is equivalent to the risk associated with heterozygous familial hypercholesterolemia
- Lp(a) should be considered in selected patients with a family history of premature CVD, and for reclassification in people who are borderline between moderate and high-risk
- ApoB analysis is recommended for risk assessment, particularly in people with high triglycerides (TG), DM, obesity or metabolic syndrome, or very low LDL-C (Mach, 2020)

National Lipid Association (NLA)

A 2021 scientific statement from the National Lipid Association on lipid measurements in the management of cardiovascular diseases: practical recommendations noted the following key points:

- LDL-C and non-HDL-C have benefits in assessing ASCVD risk and residual risk
- ApoB may help guide treatment in persons with initial lipid evaluation and persons on lipid therapy
- LDL-P assays are not standardized but may help guide treatment in persons after initial lipid evaluation for select patients
- Lp(a) can help to guide therapy in persons with primary hypercholesterolemia or those at very high risk to develop ASCVD events
- Further research is needed for advanced lipoprotein tests (e.g., LDL particle number, small dense LDL-C, or remnant cholesterol) due to lack of appropriate standardization and cross comparison of these tests utilizing different measurement techniques is difficult (Wilson et al., 2021)

A 2019 a scientific statement from the National Lipid Association on the use of lipoprotein(a) in clinical practice noted the following key points:

- The measurement of Lp(a) is reasonable in adults with:
 - Premature ASCVD (< 55 y of age in men, < 65 y of age in women)
 - Recurrent or progressive ASCVD, despite optimal lipid lowering
 - Calcific valvular aortic disease
- Patients with high Lp(a) levels may have less-than expected LDL-C lowering on statin therapy
- There is a lack of current evidence demonstrating that lowering Lp(a), independently of LDL-C, reduces ASCVD events in individuals with established ASCVD. It appears that large absolute reductions in Lp(a) may be needed to demonstrate a significant clinical benefit (Wilson et al., 2019)

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

U.S. Preventive Services Task Force (USPSTF)

The USPSTF 2018 Recommendation Statement on screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index concluded that the current evidence is insufficient to assess the balance of benefits and harms of screening for PAD and CVD risk with the ABI in asymptomatic adults.

Veterans Affairs and Department of Defense (VA/DoD)

The VA/DoD 2020 Clinical Practice Guidelines on the management of dyslipidemia for cardiovascular risk reduction suggested against the routine use of additional risk markers (e.g., high-sensitivity C-reactive protein, ankle-brachial index, coronary artery calcium) when assessing cardiovascular risk.

U.S. Food and Drug Administration (FDA)

This section is to be used for informational purposes only. FDA approval alone is not a basis for coverage.

Non-invasive blood pressure measurement system products such as the CVProfilor are numerous. Search by product code DXN to view devices. Available at:

<https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed December 12, 2023)

Measurement of CIMT is a procedure, and not subject to FDA regulation. B-mode ultrasound equipment used to measure CIMT is regulated by the FDA, but products are too numerous to list. Refer to the following website for more information (use product code IYO).

Available at:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed December 12, 2023)

Advanced lipoprotein analysis must be performed in accordance with the quality standard established in 1988 by the Clinical Laboratory Improvement Amendments (CLIA).

Products used to measure lipoprotein (a) are too numerous to list. Refer to the following website for more information (use product code DFC). Available at:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed December 12, 2023)

Products used to measure apolipoproteins are too numerous to list. Refer to the following website for more information (use product code DER or MSJ). Available at:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed December 12, 2023)

Products for the measurement of Lp-PLA2 can be found with product codes NOE and JJX at the following site: <http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm>. (Accessed December 12, 2023)

The EndoPAT 2000 received FDA 510(k) clearance (K032519) on November 12, 2003. According to the clearance summary, the ~~Endo-PAT~~EndoPAT 2000 device is a non-invasive device intended for use as a diagnostic aid in the detection of coronary artery Endothelial Dysfunction (positive or negative) using a reactive hyperemia procedure. The Endo PAT 2000 has been shown to be predictive of coronary artery Endothelial Dysfunction in the

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

following patient population: patients with signs or symptoms of ischemic heart disease, who are indicated for coronary artery angiography, but who lack angiographic evidence of obstructive coronary artery disease. The Endo PAT 2000 device is not intended for use as a screening test in the general patient population. Available at:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K032519>. (Accessed December 12, 2023)

The EndoPAT 2000 510(k) clearance summary lists the PAT 1000 RD (Itamar Medical Ltd.); (K001852) as a predicate device. Available at:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K001852>. (Accessed December 12, 2023)

The SphygmoCor System (AtCor Medical) is a series of noninvasive BP monitoring devices intended to help clinicians manage hypertensive and pre-hypertensive patients by providing central arterial pressure waveform analysis and calculations of central arterial BP and arterial stiffness. SphygmoCor XCEL System was cleared by FDA in November 2012 (K122129). Several additional 510(k) clearances had been granted earlier by FDA. The predicate device was the SphygmoCor CVMS, cleared in August 2007 (K070795). Available at:

<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K122129>. (Accessed December 12, 2023)

References

American College of Cardiology Foundation/American Heart Association Task Force. 2010 ACCF/AHA Guideline for assessment of cardiovascular risk in asymptomatic adults. American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) Guidelines for management of dyslipidemia and prevention of cardiovascular disease 2017.

American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Guideline on the assessment of cardiovascular risk. 2013.

American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Guideline on the primary prevention of cardiovascular disease. 2019.

American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Guideline for assessment of cardiovascular risk in asymptomatic adults: Executive Summary. 2010.

American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol: Executive Summary. 2018.

American Heart Association/American Stroke Association. Guidelines for the primary prevention of stroke: a statement for healthcare professionals. 2014.

American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022 Jan 1;45(Suppl 1):S144-S174.

American Society for Clinical Pathology. Thirty-five things physicians and patients should question. September 1, 2020 (31-35).

Azcui Aparicio RE, Ball J, Yiallourou S, et al. Imaging-guided evaluation of subclinical atherosclerosis to enhance cardiovascular risk prediction in asymptomatic low-to-intermediate risk individuals: a systematic review. Prev Med. 2021 Dec; 153:106819.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Bays HE, Jones PH, Orringer CE, et al. National Lipid Association Annual Summary of Clinical Lipidology 2016. J Clin Lipidol. 2016 Jan-Feb;10(1 Suppl): S1-43.

Benderly M, Sapir B, Kalter-Leibovici O, et al. Lipoprotein-associated phospholipase A and subsequent cardiovascular events and mortality among patients with coronary heart disease. Biomarkers. 2017 May - Jun;22(3-4):219-224.

Cheng Hao-Min, Chuang Shao-Yuan, Wang J, et al. Prognostic significance of mechanical biomarkers derived from pulse wave analysis for predicting long-term cardiovascular mortality in two population-based cohorts. International Journal of Cardiology 215 (2016) 388-395.

Cooper LL, Wang N, Beiser AS, et al. Digital peripheral arterial tonometry and cardiovascular disease events: The Framingham Heart Study. Stroke. 2021 Aug;52(9):2866-2873.

Day TG, Park M, Kinra S. The association between blood pressure and carotid intima-media thickness in children: a systematic review. Cardiol Young. 2017 Sep;27(7):1295-1305.

Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA. 2012 Aug 22;308(8):796-803.

Di Angelantonio E, Gao P, Pennells L, et al. Emerging risk factors collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012 Jun 20;307(23):2499-506.

Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis. 2016; 15(1):95.

Garg PK, McClellandb RL, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis. Atherosclerosis. 2015 July; 241(1): 176-182.

Geisel MH, Bauer M, Hennig F, et al. Comparison of coronary artery calcification, carotid intima-media thickness and ankle-brachial index for predicting 10-year incident cardiovascular events in the general population. Eur Heart J. 2017 Jun 14;38(23):1815-1822.

Goldstein LB, Bushnell CD, Adams RJ, et al. American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Epidemiology and Prevention; Council for High Blood Pressure Research; Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011 Feb;42(2):517-84. Erratum in: Stroke. 2011 Feb;42(2): e26.

Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010 Dec 21;122(25): e584-636.

Guardiola M, Exeter HJ, Perret C, et al. PLA2G10 gene variants, sPLA2 activity, and coronary heart disease risk. Circ Cardiovasc Genet. 2015 Apr;8(2):356-62.

Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in The Framingham Heart Study. Circulation. 2008; 117(19):24676-2474.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Handelsman Y, Jellinger PS, Guerin CK, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 Executive Summary. Endocr Pract. 2020 Oct;26(10):1196-1224.

Harris WS, Tintle NL, Imamura F, et al. Fatty Acids and Outcomes Research Consortium (FORCE). Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nat Commun. 2021 Apr 22;12(1):2329.

Hayes Inc. Evidence Analysis Research Brief. HART CADhs blood test (Prevencio Inc.) to predict risk of obstructive coronary artery disease. Lansdale, PA: Hayes, Inc.; July 2023.

Hitsumoto, Takashi. Arterial velocity pulse index as a novel marker of atherosclerosis using pulse wave analysis on high sensitivity troponin T in hypertensive patients. Cardiol Res. 2017;8(2):36-43.

Holmes MV, Simon T, Exeter HJ, et al. Secretory phospholipase A₂-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol. 2013 Nov 19;62(21):1966-76.

Hu G, Liu D, Tong H, et al. Lipoprotein-associated phospholipase A₂ activity and mass as independent risk factor of stroke: a meta-analysis. Biomed Res Int. 2019 May 20; 2019:8642784.

Kouvari M, Panagiotakos DB. The role of lipoprotein (a) in primary and secondary cardiovascular disease prevention: a systematic review of epidemiological studies. Curr Opin Cardiol. 2019a Jul;34(4):424-434.

Kouvari M, Panagiotakos DB, Chrysoshoou C, et al. Lipoprotein (a) and 10-year cardiovascular disease incidence in apparently healthy individuals: a sex-based sensitivity analysis from ATTICA cohort study. Angiology. 2019b Oct;70(9):819-829.

Kumar P, Sharma R, Misra S, et al. CIMT as a risk factor for stroke subtype: a systematic review. Eur J Clin Invest. 2020 Nov;50(11):e13348.

Kumar P, Swarnkar P, Misra S, et al. Lipoprotein (a) level as a risk factor for stroke and its subtype: A systematic review and meta-analysis. Sci Rep. 2021 Aug 2;11(1):15660.

Kuvin JT, Mammen A, Mooney P, et al. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med. 2007; 12: 13-16.

Li D, Wei W, Ran X, et al. Lipoprotein-associated phospholipase A₂ and risks of coronary heart disease and ischemic stroke in the general population: a systematic review and meta-analysis. Clin Chim Acta. 2017a Aug;471:38-45.

Li D, Zhao L, Yu J, et al. Lipoprotein-associated phospholipase A₂ in coronary heart disease: review and meta-analysis. Clin Chim Acta. 2017b Feb;465:22-29.

Liu D, Du C, Shao W, Ma G. Diagnostic role of carotid intima-media thickness for coronary artery disease: a meta-analysis. Biomed Res Int. 2020 Feb 25;2020:9879463.

Liu, Jing J, Hong, Yuling Y, Qi, Yue Y, et al. Systematic review of the association between lipoprotein-associated phospholipase A₂ and atherosclerosis. N Am J Med Sci (Boston). 2015 September 01.

Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias dyslipidemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Mahajan H, Choo J, Masaki K, et al. Serum long-chain n-3 polyunsaturated fatty acids and aortic calcification in middle-aged men: the population-based cross-sectional ERA-JUMP study. *Nutr Metab Cardiovasc Dis*. 2019 Aug;29(8):837-846.

McCarthy CP, Neumann JT, Michelhaugh SA, et al. Derivation and external validation of a high-sensitivity cardiac troponin-based proteomic model to predict the presence of obstructive coronary artery disease. *J Am Heart Assoc*. 2020 Aug 18;9(16):e017221.

Mohebi R, van Kimmenade R, McCarthy CP, et al. Performance of a multi-biomarker panel for prediction of cardiovascular event in patients with chronic kidney disease. *Int J Cardiol*. 2023 Jan 15;371:402-405.

National Heart, Lung and Blood Institute (NHLBI). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III): Final report. NIH Publication No. 02-5215. September 2002.

Neumann JT, Sørensen NA, Zeller T, et al. Application of a machine learning-driven, multibiomarker panel for prediction of incident cardiovascular events in patients with suspected myocardial infarction. *Biomark Med*. 2020 Jun;14(9):775-784.

Newman C, Blaha M, Boord J, et al. Lipid management in patients with endocrine disorders: an Endocrine Society Clinical Practice Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 2020, Vol. 105, No. 12, 3613-3682.

Nonterah EA, Crowther NJ, Klipstein-Grobusch K, et al. Racial and ethnic differences in the association between classical cardiovascular risk factors and common carotid intima-media thickness: An individual participant data meta-analysis. *J Am Heart Assoc*. 2022 Aug 2;11(15):e023704.

Olson N, O'Meara ES, Jenny NS, et al. Lipoprotein-associated phospholipase A2 and risk of venous thrombosis in older adults. *Am J Hematol*. 2008;83(7):524-527.

Orfanos P, Fonseca AF, Hu X, et al. Burden of elevated lipoprotein(a) among patients with atherosclerotic cardiovascular disease: Evidence from a systematic literature review and feasibility assessment of meta-analysis. *PLoS One*. 2023 Nov 20;18(11):e0294250.

Prevensio Inc. HART tests. <https://www.prevensiomed.com/>. Accessed December 27, 2022.

Piko N, Bevc S, Hojs R, et al. The association between pulse wave analysis, carotid-femoral pulse wave velocity and peripheral arterial disease in patients with ischemic heart disease. *BMC Cardiovasc Disord*. 2021 Jan 13;21(1):33.

Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein (a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2022 Jan;42(1):e48-e60.

Roman MJ, Naqvi TZ, Gardin JM, et al. American Society of Echocardiography Report. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society for Vascular Medicine and Biology. *Vasc Med*. 2006; 11: 201-211.

Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. *European Heart Journal*. 31 (9) (pp 1142-1148), 2010.

Sang T, Cheng N, Dang A, et al. Lipoprotein (a) is associated with poor long-term prognosis in patients aged 80 years and older with acute coronary syndrome. *J Clin Lipidol*. 2021 May-Jun;15(3):466-476.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Schnabel RB, Magnussen C, Schulz A, et al. Gutenberg Health Study investigators. Noninvasive peripheral vascular function, incident cardiovascular disease, and mortality in the general population. *Cardiovasc Res*. 2021 Mar 16;:cvab087.

Sequí-Domínguez I, Caverro-Redondo I, Álvarez-Bueno C, et al. Accuracy of pulse wave velocity predicting cardiovascular and all-cause mortality. A systematic review and meta-analysis. *J Clin Med*. 2020 Jul 2;9(7):2080.

Shah NP, Wang Q, Wolski KE, et al. The role of lipoprotein (a) as a marker of residual risk in patients with diabetes and established cardiovascular disease on optimal medical therapy: post hoc analysis of ACCELERATE. *Diabetes Care*. 2020 Feb;43(2):e22-e24.

Smith JW, Barlas RS, Mamas MA, et al. Association between serum secretory phospholipase A2 and risk of ischaemic stroke. *Eur J Neurol*. 2021 Nov;28(11):3650-3655.

Task Force Members; ESC National Cardiac Societies; ESC Committee for Practice Guidelines (CPG). Corrigendum to "2019 ESC/EAS Guidelines for the management of [dyslipidaemias](#) [dyslipidemias](#): lipid modification to reduce cardiovascular risk" *Atherosclerosis* 290 (2019) 140-205.

Tian Y, Jia H, Li S, et al. The associations of stroke, transient ischemic attack, and/or stroke-related recurrent vascular events with lipoprotein-associated phospholipase A2: a systematic review and meta-analysis. *Medicine (Baltimore)*. 2017 Dec;96(51):e9413.

[Tschiderer L, Seekircher L, Izzo R, et al. Association of intima-media thickness measured at the common carotid artery with incident carotid plaque: individual participant data meta-analysis of 20 prospective studies. J Am Heart Assoc. 2023 Jun 20;12\(12\):e027657.](#)

[U.S.](#) Preventive Services Task Force Recommendation Statement. Screening for peripheral artery disease and cardiovascular disease risk assessment with the ankle-brachial index. July 10, 2018.

van den Heuvel M, Sorop O, Musters PJ, et al. Peripheral arterial tonometry cannot detect patients at low risk of coronary artery disease. *Neth Heart J*. 2015 Sep;23(10):468-74.

Venuraju S, Jeevarethinam A, Mehta VS, et al. Predicting severity of coronary artery disease in patients with diabetes using endothelial function measured with peripheral arterial tonometry: PROCEED study. *Angiology*. 2019 Aug;70(7):613-620.

Veterans Affairs and Department of Defense (VA/DoD) Clinical Practice Guidelines: The management of dyslipidemia for cardiovascular risk reduction. Version 4.0 - June 2020.

Villines T, Hsu L, Blackshear C, et al. Cardiovascular events in black Americans (From the Jackson Heart Study). *Am J Cardiol* 2017;:120:1528-1532.

Waldeyer C, Makarova N, Zeller T, et al. [Lipoprotein \(a\) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J](#). 2017 Apr 24.

[White-Al Habeeb NMA, Higgins V, Venner AA, et al. Canadian Society of Clinical Chemists harmonized clinical laboratory lipid reporting recommendations on the basis of the 2021 Canadian Cardiovascular Society lipid guidelines. Can J Cardiol. 2022 Aug;38\(8\):1180-1188.](#)

Willeit P, Tschiderer L, Allara E. Carotid intima-media thickness progression as surrogate marker for cardiovascular risk: meta-analysis of 119 clinical trials involving 100,667 patients. *Circulation*. 2020 Aug 18;142(7):621-642.

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Wilson DP, Jacobson TA, Jones PH, et al. Use of lipoprotein (a) in clinical practice: a biomarker whose time has come. a scientific statement from the National Lipid Association. J Clin Lipidol. 2019 May-Jun;13(3):374-392.

Wilson PWF, Jacobson TA, Martin SS, et al. Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group. J Clin Lipidol. 2021 Sep-Oct;15(5):629-648.

Xin H, Chen ZY, Lv XB, et al. Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction. Eur Rev Med Pharmacol Sci. 2013 Apr;17(8):999-1004.

Younus A, Humayun C, Ahmad R et al. Lipoprotein-associated phospholipase A2 and its relationship with markers of subclinical cardiovascular disease: a systematic review. Journal of Clinical Lipidology, Vol 11, No 2, April 2017.

Zhang F, Guo J, Yang F, Zhou Y. Lp-PLA2 evaluates the severity of carotid artery stenosis and predicts the occurrence of cerebrovascular events in high stroke-risk populations. J Clin Lab Anal. 2021 Mar;35(3):e23691.

Zheng S, Qiu M, Wu JHY, et al. Long-chain omega-3 polyunsaturated fatty acids and the risk of heart failure. Ther Adv Chronic Dis. 2022 Mar 18;13:20406223221081616.

Policy History/Revision Information

Date	Summary of Changes
<u>TBD</u>	<p><u>Coverage Rationale</u></p> <ul style="list-style-type: none"> <u>Revised list of unproven and not medically necessary multi-protein diagnostic biomarkers:</u> <ul style="list-style-type: none"> <u>Added:</u> <ul style="list-style-type: none"> <u>Analysis of protein biomarkers by aptamer-based microarray and algorithm</u> <u>7 protein (IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3) with algorithm and reported as a risk score</u> <u>Replaced "3 proteins [high sensitivity (HS) troponin, adiponectin, and kidney injury molecule-1 (KIM-1)]" with "3 proteins [high sensitivity (HS) troponin, adiponectin, and kidney injury molecule-1 (KIM-1)] with algorithm and reported as a risk score"</u> <p><u>Applicable Codes</u></p> <ul style="list-style-type: none"> <u>Added CPT codes 0019M and 0415U</u> <p><u>Supporting Information</u></p> <ul style="list-style-type: none"> <u>Updated Description of Services, Clinical Evidence, and References sections to reflect the most current information</u> <u>Archived previous policy version CS015LA.N</u>

UnitedHealthcare, Inc. ("UHC") Proprietary and Confidential Information: The information contained in this document is confidential, proprietary and the sole property of UHC. The recipient of this information agrees not to disclose or use it for any purpose other than to facilitate UHC's compliance with applicable State Medicaid contractual requirements. Any other use or disclosure is strictly prohibited and requires the express written consent of UHC.

Instructions for Use

This Medical Policy provides assistance in interpreting UnitedHealthcare standard benefit plans. When deciding coverage, the federal, state or contractual requirements for benefit plan coverage must be referenced as the terms of the federal, state or contractual requirements for benefit plan coverage may differ from the standard benefit plan. In the event of a conflict, the federal, state or contractual requirements for benefit plan coverage govern. Before using this policy, please check the federal, state or contractual requirements for benefit plan coverage. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Policy is provided for informational purposes. It does not constitute medical advice.

UnitedHealthcare may also use tools developed by third parties, such as the InterQual® criteria, to assist us in administering health benefits. The UnitedHealthcare Medical Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.

DRAFT